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ABSTRACT 
FORMULATION AND CHARACTERIZATION OF LIPOGELS AS A TUNABLE DELIVERY 
SCAFFOLD 
 
FEBRUARY 2018 
CELIA C. HOMYAK 
B.S., WINONA STATE UNIVERSITY 
PH.D., UNIVERSITY OF MASSACHUSETTS AMHERST 
Directed by: Professor Sankaran Thayumanavan 
Nanomedicines within the clinic commonly utilize lipid-based scaffolds due to their 
aqueous assembly and non-covalent dual-guest loading capabilities. Nevertheless, poor stability 
in vivo and premature guest release remains a challenge with these systems. Polymeric 
nanomaterials are a popular alternative due to their good stability in vivo with controllable guest 
release. A caveat to polymeric scaffolds though, is the excess synthetic effort involved for non-
covalent dual-drug encapsulation. Benefit lies in harnessing advantages of lipid and polymeric 
materials via lipid-polymer hybrid scaffold. Such materials have promise due to their dual-
encapsulation and dual-stimuli-sensitive characteristics. The need to better understand these 
materials led us to formulate a lipid coated polymer gel or lipogel (LG). Herein we formulated a 
new LG scaffold and established methods to characterize its formation, purification, dual-guest 
encapsulation, and stability. Further analysis confirmed LGs were dual-stimuli-sensitive and non-
toxic with controllable intracellular uptake profile, which highlighted their potential for 
parenteral administration. Initial monitoring of LG variant stability under oral administration 
conditions was also done to display its versatility and expand our material scope. Overall the 
simplicity of formation, dual-guest encapsulation, dual-stimuli-sensitivity, and tunable core/shell 
properties of LGs highlight their potential as a nanotherapeutic delivery scaffold.  
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CHAPTER 1 
INTRODUCTIONa 
1.1  Motivations 
Nanotechnology has been utilized within biomedical research applications for more than 
50 years and has exponentially grown since the National Institutes of Health launched the 
National Nanotechnology Initiative in 2000.1 Recent advancements in pre-clinical, clinical, and 
marketed nanomedicines have shown that these scaffolds are indeed promising therapeutic 
carriers. Enhanced drug sequestration, stability, and target site accumulation of nanomedicines 
increase therapeutic windows, while decreasing off-target side effects, which are two of the 
biggest setbacks in current therapeutics. The ability to fine tune nanomaterial properties such as 
drug encapsulation, shape, size, surface functionality, stimuli-sensitivity, and serum stability is 
further assurance to their utility in therapeutics. Despite the large array of material capabilities, 
there has yet to be a successful boom of clinically available nanotherapeutics. This is likely due 
to the gap in understanding and characterization of nanomaterials interactions throughout the 
biological system. Therefore, the overarching emphasis of this dissertation is focused on 
understanding the biological barriers and how current nanotherapeutics overcome them to 
design scaffolds tunable for different administration routes.2   
1.2 Figure of merit for drug delivery vehicle 
Many chemical and physical characteristics must be taken into account for successful 
polymer nanotherapeutics. Beyond needing facile polymer syntheses and assembly formation 
                                                                    
a Content of this chapter was adapted from published manuscript: 
2 Homyak, C.; Anson, F.; Thayumanavan, S. In Comprehensive Supramolecular Chemistry II; 
Atwood, J. L., Ed.; Elsevier, 2017; Vol. 5, pp. 227–254. 
2 
techniques, characteristics such as size, surface functionality, guest encapsulation, stimuli-
sensitivity, toxicity, and industrial relevance need to be accounted for in successfully engineering 
nanotherapeutics.3  
1.2.1 Size & shape 
Once in circulation, the first obstacle of nanotherapeutics is avoiding reticuloendothelial 
system (RES) clearance predominantly within the liver, spleen, and lymph nodes.4 Foreign 
materials are naturally removed within the body via the RES based on size and/or functionality. 
Particles smaller than 5 nm and larger than 200 nm will be filtered out via the kidney or spleen 
respectively, while the optimal size for extended circulation half-life is ~100 nm.4 Considering the 
enhanced permeation and retention (EPR) effect, epithelial and vascular extravasations range 
between 50-100 nm within the liver,4 and 200 nm-2000 nm within tumors.5 Studies have shown 
that particles with a hydrodynamic radius smaller than 100 nm, have highest tumor accumulation 
in vivo.5,6 Specifically nanomaterials with sizes between 20-50 nm have shown increased disease 
accumulation, although this is dependent on the disease model and other particle 
characteristics.5 Cell internalization is also greatly dependent on particle size. Endocytosis of 
nanomedicines is traditionally limited to a particle size range of 10-100 nm, although recent 
reports have shown that it is possible for larger (~5 uM) sized particles to undergo endocytosis.7 
Due to limited size penetration of subcellular organelle membranes (e.g. nucleus <9 nm),8 it could 
also be advantageous to utilize multi-level nanomedicines. Such materials would have a larger 
size or functionality throughout blood circulation, but following intracellular uptake, breakdown 
and release, smaller nanoparticles or small molecule drugs.  
Beyond size, the shape of nanomedicines has been shown to effect circulation time and 
accumulation throughout the biological system.4 The larger contact surface area and tumbling 
3 
of non-spherical particles is thought to be a good way for enhancing nanomedicine interactions 
with diseased cells.4 Compilation of distribution studies have shown that rod or disc shaped 
nanoparticles have higher delivery efficiency than typical spherical particles.4,6 Addition of 
surface functionalities such as charge or targeting ligands is another route to enhance circulation 
stability, extracellular accumulation, and intracellular uptake of nanomaterials.4,5,7,8  
1.2.2 Surface functionality and stimuli-sensitivity 
1.2.2.1 Surface functionality  
By modifying surface functionality of nanocarriers, circulation stability and targeting 
characteristics can be greatly improved within the biological system. Additionally, modifications, 
which make nanocarriers undetectable within circulation, are important to avoid opsonization 
and immune clearance via the RES. Applying a poly(ethylene glycol) (PEG) coating (PEGylation) 
to the surface of particles can help avoid RES clearance to greatly enhance circulation lifetime of 
nanomaterials.4,9,10 PEG’s high water coordination11 provides a hydrating shell, which allows 
nanomaterials to be undetected in circulation, inhibiting immune clearance and excretion. PEG 
product coatings have been FDA approved since 1990 and many successful PEG-protein 
therapeutics have been developed such as Pegasys® and PEG-Intron® for Heptatitus C, and 
Cimzia® for Chron’s disease and rheumethroid arthritis treatment.12 There are also examples in 
which PEGylation enhances small molecule chemotherapeutics within liposomes, such as the 
marketed chemotherapeutic Doxil.11 The improved serum retention time, stability to metabolic 
enzymes and quality of both small molecule and protein PEGylated drugs leaves it a facile and 
popular surface modification.11–13 Similarly, polysaccharide coatings are considered to render 
nanoparticles as “stealthy”, since the resulting biocompatible and biodegradable nanoparticles 
demonstrate increased blood circulation time.13,14 Beyond surface masking to enhance 
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circulation time, further surface functionalization can provide for specifically targeting of disease 
cells within the body.  
Depending on the surface functionality that is added onto nanomedicines, they can be 
classified as passive or active targeting therapeutics. Passive targeting carriers typically rely on 
specific size accumulation via the EPR effect, although modification of nanoparticle surface 
charge can also be used to passively target cell uptake and sub-cellular pathway delivery. This 
comes with the caveat that neutral particles are known to have more efficient biodistribution and 
delivery in vivo than charged particles.6 For example, polysaccharides are used as neutral (e.g. 
DX), cationic (e.g. CS), or anionic (e.g. HA, AL) coatings, can increase tissue and mucus adhesion 
throughout the biological system.13,15–17 Cationic and anionic materials allow for intra and 
extracellular interactions, which are discussed in more detail within Chapter 3 and 4.4,5,7,8 Passive 
targeting is utilized in majority of currently FDA approved nanomedicines,18 although utilizing 
active targeting within nanomedicines can allow for more specific target accumulation and 
release.  
Active targeting therapeutics specifically interact with proteins or enzymes expressed on 
particular phenotypes of target cells.3 Utilizing this specific carrier-target interaction can also 
minimize off target interactions in vivo.3 Such targeting is typically done via surface 
functionalization of nanotherapeutics with small molecule ligands, peptides, antibodies, 
proteins, sugar moieties, or aptamers (Figure 0.1).19 Disease cell receptors allow for actively 
triggering specific cell-uptake and intracellular organelle delivery,7,8,20 and are being utilized for 
active targeting based nanomaterials in current clinical trials.18 Despite the promising results of 
active targeting therapeutics, the fate of surface ligands and material stability in vivo remains 
unclear, which are significant barriers for current approaches.21 Another way to ensure more site-
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selective drug release is through adding stimuli-sensitive moieties within nanocarriers to release 
therapeutics under specific biological stimuli. 
 
Figure 0.1 Size and surface variations of nanotherapeutics2  
1.2.2.2 Stimuli-sensitivity  
Site-specific stimuli-sensitive release is vital to targeted therapeutic delivery. Utilizing 
specific stimuli at or around desired targets is key to releasing therapeutics at disease sites, while 
also minimizing off-target release. A series of work has been done on stimuli-sensitive polymer 
materials, and discussed in greater detail elsewhere.19,22–24 Within this section, the stimuli-
sensitive release conducted via different chemical, enzymatic, or physical interactions, are briefly 
discussed. (Figure 0.2)  
PEGylation 
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Figure 0.2 Mechanisms of nanomaterial stimuli-sensitive guest release2 
Chemically triggered release can be done via the various intra- and extra-cellular changes 
in pH or redox.3 Depending on the disease and mode of cell uptake pH triggered release can be 
targeted towards extra- or intra-cellular areas. Specific pH barriers throughout biological targets 
and barriers are highlighted more specifically in Chapter 3. In general, low pH occurs in tissues 
throughout the skin surface (pH ~5-7), gastrointestinal tract (stomach pH 1-2), golgi apparatus 
(pH ~6.4) and lysosomes (pH ~4.5-5.0). Additionally, tumor cells have a decreased extracellular 
pH of ~6.2-6.9, allowing for preferential targeting over healthy cells.25 Since there are many 
detailed literature reviews on acid-sensitive polymer systems,19,24–29 we have highlighted only 
general moieties and functions of pH-sensitive nanotherapeutics. Acid-sensitive polymer 
systems contain either ionizable or acid-labile moieties.25,26 Systems with ionizable moieties (e.g. 
primary amines or carboxylic acids) are destabilized in response to pH variations, causing 
changes in nanoparticle packing and subsequent guest release.25 Alternatively, acid-labile 
polymers have covalent linkages (e.g. acetal,30,31 ketal, imine, or hydrazone) which cleave under 
acidic pH, causing subsequent drug release. Beyond pH sensitive materials, redox stimuli can 
allow for even more efficient and site specific release.25 In particular, a more promising target 
specific redox stimulus is from the higher concentrations of reducing agent glutathione (GSH) 
found within the cytosol (2-10 mM),25 relative to blood plasma (2-20 μM).25 Intracellular 
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concentration of GSH in tumor cells can also be up to 4 times greater than normal tissue,19 
making redox-sensitive release popular for many polymer nanotherapeutics.3,19,22,25,29,32 A series 
of current reviews are good sources for the vast amount of redox-sensitive nanomedicines.19,23–
25,29 These systems typically contain disulfide linkages, which are stable under general biological 
milieu, but cleave under higher GSH concentrations. Even greater specificity in stimuli-sensitive 
release can be accomplished utilizing enzymatic interactions.  
Although enzymes are also found in healthy tissues, certain enzymes are up-regulated 
as a result of various diseases allowing for site-specific stimuli-sensitive release.19 Proteases, 
phospholipases, and glycosidases, are a few commonly up-regulated enzymes present in various 
disease areas such as cancer, immunodeficiency, inflammation, or infection.25 Enzyme-sensitive 
polymer systems can be either degraded to release drugs, or alternatively have a change in 
macroscale structure, causing more controlled drug release.25 Both intra- and extra-cellular 
enzyme expressions can be targeted with enzyme-sensitive systems. Alternative to chemical or 
enzymatic stimuli, there are a series of physical stimuli utilized throughout nanomedicine to 
externally trigger site-specific drug release or penetration.   
Carriers can also be designed to release upon physical stimuli such as temperature, light, 
ultrasound, or magnetic field.19 Thermo-responsive systems are generally designed to be stable 
at physiological temperature (~37 °C), but rapidly destabilize and release when locally heated 
(~40-42 °C).29,33 Ultraviolet (UV) light (10-400 nm)25 can be utilized in nanomaterials containing 
reactive derivatives such as o-nitrobenzyl, coumarin, azobenzene, and 2-diazo-1,2-
napthoquinone.25 Potential destruction of biological components at high energy UV wavelengths 
and the minimal penentration of light throughout biological tissues limits the applicability of 
light-sensitive nanotherapeutics.25 Ultrasound (US) is less destructive than UV light, and is more 
commonly used for both imaging and enhanced therapeutic permeation.17,25,34 Oscillating 
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pressure formed from US waves causes increased temperature and pore formation within both 
synthetic and biological systems.19 Typically lipid- and polymer- based liposomes19 or 
microbubbles25 containing a gaseous core are utilized for US responsive systems.25 Compared to 
either UV or US, magnetic field stimulus is even less invasive, with minimal interactions 
throughout biological tissues.25 Magnetic-responsive nanoparticle19,25 delivery offers increased 
directing/release control and higher tissue permeability (up to 3 cm)25 in comparison to other 
chemical and physical responsive systems. 
1.2.3 Therapeutic encapsulation, toxicity, and biodistribution 
1.2.3.1 Encapsulation capacity and stability 
To ensure therapeutic effect, drug molecules are commonly administered in larger doses 
due to their insolubility, metabolization, and/or excretion within the human body. One of the key 
benefits to nanotherapeutics is the ability to decrease this minimum effective dose through 
encapsulating, solubilizing, and protecting larger amounts of drug molecules.3 Guest 
encapsulation is measured as a percent of encapsulated drug within a polymer solution, which is 
related to the distribution coefficient of the drug between the carrier and bulk solution.3 Loading 
capacity for typical vehicles ranges from 5-60 %,3 and is largely dependent on the material 
scaffold and guest characteristics. Maximizing the guest loading is ideal, although utilizing a 
more effective therapeutic guest can compensate for lower carrier loading capacity.  
Delivery scaffolds must also stably protect guest molecules to avoid premature guest 
release, before reaching the biological target. With that, nanomedicines need to withstand 
turbulent flow of circulation without having any release or transfer of guests from interactions 
with red blood cells or lipophilic membranes.3 Within the extracellular space and in blood 
circulation the polymer carrier can be easily hydrolyzed or cleaved via change in pH or also by 
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enzymes causing premature guest release.3 Beyond stably encapsulating increasing amounts of 
therapeutics, nanomaterial toxicity must also be accounted for. 
1.2.3.2 Toxicity & biodistribution  
Nanocarriers themselves must be inherently non-toxic and biocompatible to avoid 
immune recognition within circulation. Toxicity has been arising when transitioning targeting 
nanotherapeutics from in vivo animal models to clinical trials. To determine the key factors of 
this toxicity and eliminate toxicity factors from nanomedicine designs, it is also beneficial to 
utilize non-toxic materials, which degrade into generally regarded as safe (GRAS) components. 
The long standing EPR effect has been most studied in contributing to nanoparticle 
disease site accumulation.5 The EPR effect is the ability of nanomaterials to accumulate within 
leaky tumor vasculature areas. This is due to the rapid formation of disease tissues and 
vasculature causing discontinuous basal epithelium within mother vessels. This discontinuity 
forms fenestrations in which small particles can extravasate to within tumor sites. Due to both 
particle size and decreased lymphatic drainage within tumor sites, nanoparticles can accumulate 
within fenestrations to trigger passive or active tumor delivery. As of now, liposomal drugs and 
polymer-drug conjugates are dominating as successful nanotherapeutics due to their long half-
life, facilitating passive tissue accumulation.35 Active targeting nanoparticles have shown a 
higher tumor accumulation in comparison to passive targeting nanoparticles, although this 
difference is not significant.6 In addition to current work, future in vitro models and clinical studies 
are needed to determine the key characteristics of polymer and/or lipid nanomedicines effecting 
toxicity and distribution.  
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1.2.4 Translating to the clinic  
Nanotherapeutics that become FDA approved and marketed need to be translatable 
within industrial manufacturing processes. Typically, fundamental polymer nanotherapeutics 
are synthesized in very small scale, in many cases involving complex synthetic effort. In order to 
be successful within industry, these small-scale processes need to be scalable by orders of 
magnitude for feasible industrial production (i.e. mL to L scale). With this in mind, the synthetic 
processes need to be facile and scalable, utilizing materials that may be readily obtained through 
the supply chain. Also, the batch-to-batch variability and dispersity needs to be well controlled 
since this is a common problem with nanotherapeutic production.6 Furthermore, there is a large 
cost associated with current nanomedicines due to the large volumes needed for sufficient tumor 
accumulation.6 The only way to overcome this is by tuning initial nanomaterial designs to 
increase therapeutic loading and target distribution/accumulation in vivo. In addition to this, the 
route of administration can greatly impact the rate of success of therapeutics.  
Most nanotherapeutics are targeted for intravenous administration. However, utilizing 
alternative routes of administration (e.g. transdermal, oral, pulmonary) within therapeutic 
design will lead to higher clinical and industrial impact. Although, overcoming the harsh 
biological barriers of transdermal, oral, and pulmonary administration is not a trivial task, which 
is further discussed in Chapter 4. Providing simple formulations to tune nanomedicines for 
different administration routes would have great impact, which is a key motivation throughout 
this dissertation work. Overall greater understanding of materials’ complex properties and 
biological interactions throughout administration routes are needed for successfully designing 
such tunable nanotherapeutics.  
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1.2.5 Crossing biological barriers  
Regardless of the route of administration, it is vital to consider the possible biological 
barriers each therapeutic will encounter for ensuring delivery of active therapeutics to the 
desired target. Many biological barriers for intracellular,7,8,36 parenteral,21 transdermal,37 and oral 
administration38 are highlighted throughout the literature. Despite the extensive pre-clinical and 
clinical research on nanomedicines, a global understanding of how nanomedicines cross these 
barriers has not been reached. Since the biological barriers are vastly different for different 
routes of administration, we have focused on designing tunable nanomaterials for intravenous 
(IV) (specifically intracellular) and oral delivery applications. Current strategies for overcoming 
intracellular and oral barriers via polymer and lipid nanomaterial design will be emphasized in 
more detail within Chapter 3 and 4, respectively.   
1.3 Clinically relevant nanomaterial scaffolds  
Both organic and inorganic nanomaterials have been extensively studied pre-clinically 
and clinically for sensing, imaging, and therapy applications. Clinically relevant inorganic 
nanomaterials, such as iron-oxide, silica, or gold based materials, are utilized in various types of 
therapeutic and sensing applications.18 More biocompatible organics, such as proteins, 
liposomes, and polymers also have great clinical relevance throughout sensing, diagnostics, and 
therapeutics.18 Due to the high biocompatibility of liposomes and biomolecules, they are popular 
for use in therapeutics. However, instability of such systems within the biological system, limits 
their use in nanotherapeutics. The extensive research and development of polymer science has 
led to more tunable polymer scaffolds with desired chemical and physical characteristics (e.g. 
facile synthesis, aqueous self-assembly, morphology control). A vast amount of this work utilizes 
polymers for therapeutic applications, which is setting guidelines for materials and processes 
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that hold great potential in designing nanomedicines.21 Throughout this work, we have focused 
on using hybrid lipid and polymer materials, which are discussed in more detail within this 
section.  
1.3.1 Lipid-based  
Lipid based systems for therapeutics18 are composed of semi-liquid/liquid formulations 
(micelle, emulsion, or liposomes (LS)), or solid formulations (solid lipid nanoparticle (SLN)).39 All 
of the formulations have applicability for hydrophobic guest delivery, although for hydrophilic 
guest delivery (e.g. PPs) LS and SLNs are frequently utilized. SLNs have established formation 
processes in industrial settings, although this typically requires exposure of lipid and guest 
materials to toxic organic solvents during processing, which is known to denature sensitive 
biomolecule guests. For this reason, we chose to pursue LSs due to their complete aqueous 
formation with dual-encapsulation ability.  
LSs are one of the few marketed nanomedicines are found in a vast amount of pre-clinical 
and clinical technologies for an array of therapies (e.g. vaccines, cancer, gene therapy).18,40,4142–45 
The majority of approved nanomedicines utilize liposome scaffolds with polymer 
functionalization (e.g. PEGylated), such as cancer therapeutics Doxil® (Janssen 1995), and 
Onivyde (Merrimack 2015).18 Nanocort (Enceladus and Sun Pharma Global) is also a PEGylated 
liposome nanotherapeutic for rheumatoid arthritis treatment within Phase 3 clinical trials.18 
Another PEGylated liposome in Phase 3 clinical trials is MM-302 (Merrimack Pharmaceuticals). 
MM-302 is one of the few nanomedicines within clinical trials, which utilizes targeting capabilities 
of HER2-targeted cancer therapy.18  
The aqueous self-assembly, hydrophobic/hydrophilic guest encapsulation, and tunable 
properties (i.e. size, surface functionality, stimuli-sensitivity) make LSs advantageous carriers for 
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multi-drug delivery. However, a caveat to LSs is their subpar in vivo stability and lack of controlled 
guest release mechanisms. Typically, LSs undergo a “burst” type release, meaning both 
hydrophilic and hydrophobic guest molecules are simultaneously released after destabilization. 
This is a large setback since LSs are known to be readily destabilized and cleared by the 
reticuloendothelial system (RES) within blood circulation. Stability and functionality of LSs can 
be easily changed by incorporating a covalently modified lipid within their lipid bilayer, (e.g. lipid 
conjugated to targeting ligands,46 PEG,44 or fluorescent dyes47). As noted above, PEGylation is a 
popular route of avoiding the RES system and used within clinical LS systems today. Despite 
PEGylation, LSs still have lower stability and minimal release characteristics in comparison to 
alternative polymeric nanotherapeutics being exploited.2  
1.3.2 Polymeric  
Polymers introduce a robust framework for encapsulation and protection of fragile 
therapeutics. Acting as a protective barrier, polymer carriers decrease susceptibility of cargo 
degradation under harmful conditions within the human body.6 Polymeric nanomaterials hold 
promise because they have a variety of tunable properties including shape, size, and surface 
functionality. In addition, polymer systems can be easily tailored for high stability in vivo, while 
also controlling guest release under specific biologically relevant stimuli such as pH, redox, light, 
or temperature.2,19,25,48–50 Additionally, polymer scaffolds have the ability to encapsulate 
hydrophilic or hydrophobic guests, although thoughtful design is necessary to have facile control 
over such encapsulation, formation, and delivery capabilities. There are an array of synthetic (e.g. 
amphiphilic copolymers, hydrogels, PEG) and natural (e.g. proteins, polysaccharides) polymers 
commonly known to fulfill these desired characteristics as nanomedicines, which are discussed 
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in great detail elsewhere.2 Within each dissertation chapter, we briefly discuss specific type of 
polymer materials and their utility within our specific scaffold designs.  
Polymer based nanomaterial scaffolds have also been FDA approved. A key example of 
this is Abraxane® (Celgene FDA-2005 EMA-2008), which is an albumin-paclitaxel nanoparticle 
utilized in cancer therapeutics. Genexol-PM® (Samyang Biophamaceuticals FDA-2016)51 is also 
approved for paclitaxel delivery but is a polymer micelle based material. Similar polymer micelle 
materials within Phase 3 clinical trials are NK105 (Nippon Kayaku) a paclitaxel-polymer micelle, 
and NC-6004 Nanoplatin (Nanocarrier), a PEG-polyamino acid derivative.18 Beyond IV, SEL-068 
(Selecta Biosciences) is a SC administered polymer nanoparticle for nicotine vaccine within 
Phase 1 clinical trials.32,52 Beyond parenteral administration, there are also polymer materials 
being clinically tested for oral delivery as well. An example of an orally administered polymer 
formulation is Transient Permeability Enhancer (TPETM) (Chiasma), which is a formulation within 
Phase 3 clinical trials, which combines absorption-enhancers into a polymer matrix for oral PP 
delivery.53 Similarly, upcoming reports are revealing promising polymer-based nanomaterials 
within Phase 1 clinical trials, such as Access Pharmaceutical’s vitamin B12 coated insulin DX 
nanoparticle and NOD Pharmaceutical’s insulin loaded bioadhesive nanoparticle.54 Some more 
examples of materials, which are being tested but not yet in clinical trials utilize biodegradable 
polymer nanosphere are (APH-0907 (Aphios Corp.)),54or chitosan (CS) and poly(glutamic acid) 
nanosystems for oral delivery (Nanomega).55  
Many polymer nanomaterials have successfully reached pre-clinical trials, but few have 
reached the clinical market.2 The benefits of clinically relevant LS systems (with dual-loading 
capabilities), along with more stable and tunable polymer nanomaterials (with controllable guest 
release) have spiked interest in forming hybrid lipid-polymer materials.56–59 Such systems hold 
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great potential due to their enhanced properties in comparison to parent LS or polymer 
materials.  
1.3.3 Lipid-polymer hybrids  
Lipid-polymer hybrid nanomaterials have been of recent interest due to the stability of 
typical core composite materials and biocompatibility of lipids.60,61 Typically polymer 
nanoparticles can be coated with a lipid monolayer or bilayer depending on core nanoparticle 
composition being either hydrophobic or hydrophilic, respectively. Lipid coated hydrophobic 
polymer nanoparticles for mono- or multi-drug delivery have shown clinical relevance, although 
will not be discussed within this dissertation.61 Due to the high impact of protecting and 
delivering both hydrophobic small molecules and larger hydrophilic biomolecules (e.g. proteins 
or peptides), we have focused on lipid coated polymer gels (lipogels).  
Lipogels (LGs) are of interest due to their ability to harness the biocompatibility and 
stability advantages of current lipid and polymer nanotherapeutics, respectively. 30,56–58,61–70 
Typically LGs are formed through a one- or two-step self-assembly process, to non-covalently 
encapsulate guest molecules.61  A large advantage to LGs is their ability to non-covalently 
encapsulate both hydrophilic (within the core) and/or hydrophobic (within lipid bilayer) guest 
molecules.30,56,57,60,67,70 The process for such guest encapsulation and LG formation are described 
in more detail within Chapter 2. Moreover, the separately tunable characteristics of the lipid shell 
and polymer core allows for making LGs stimuli-sensitive, in which core/shell components are 
responsive to change in temperature65,71 or pH,30 which will be discussed in more detail within 
Chapter 3.  
To our knowledge, LGs have yet to make it to the clinical market, although many reports 
have shown them to be applicable to therapy, sensing, and/or diagnostics.60 The array of lipids, 
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and/or guest molecules utilized in reports have shed light on methods of characterizing particle 
formation, purification and characterization. However, the complex nature of dual-guest loaded 
and/or dual-stimuli-sensitive LGs systems makes them difficult to monitor within solution and 
biological settings, which is likely hindering their clinical success. Ways in which we were able to 
overcome such challenges in regard to dual-encapsulation and dual-sensitive LGs are highlighted 
in more detail throughout Chapters 2 and 3, respectively.   
1.4 Dissertation overview  
1.4.1 Motivations and themes 
As discussed above, lipogels hold potential to exhibit enhanced stability and loading 
capabilities in comparison to parent liposome or polymer materials. Additionally, great potential 
lies in the simplicity of LG aqueous assembly, dual-stimuli-responsive character, and ability to 
non-covalently encapsulate hydrophilic and/or hydrophobic guest molecules. Tunability of LG 
core/shell characteristics allow for potential use in various delivery applications. However, a 
challenge lies in characterizing such complex nanomaterials, which is only magnified, when 
trying to monitor material/guest properties within complex biological environments. Within this 
dissertation work, we have established new means to characterize LGs from initial formation to 
stability within both simple and complex biological solutions.  
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1.4.2 Formulation and characterization of dual-guest loaded LG scaffold 
 
Figure 0.3 Single-pot formation of dual-guest loaded lipogel (LG)72 
Within Chapter 2, we describe lipogel (LG) formulation formed via a single-pot 
methodology, where self-assembling liposomes template a UV-curable polymer gel core (Figure 
0.3). Formation, purification, and encapsulation efficiency was characterized via previously 
established methods using dynamic light scattering (DLS), matrix-assisted laser desorption 
ionization-mass spectrometry (MALDI-MS), UV-Visible spectroscopy, and/or fluorescence 
spectroscopy. Additional methods of characterizing purification and dual-guest encapsulation 
via single particle total internal reflection fluorescence (TIRF) microscopy were also established, 
and shown to correlate well with other characterization techniques (e.g. fluorescence, DLS). 
Analysis of shelf-life stability confirmed the formulated LGs were stable in solution for several 
months, which led us to further explore this LG formulation for its dual-responsive character 
along with capability for intracellular delivery.  
liposome	(LS)
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1.4.3 Characterization of dual-stimuli-sensitive LG for intracellular delivery  
 
Figure 0.4 Characterizing LG dual-stimuli-sensitivity 
The stimuli-sensitivity, toxicity, and intracellular uptake of our LG formulation is covered 
within Chapter 3.   Dual-stimuli-sensitivity of the pH-sensitive lipid shell and redox-sensitive 
polymer nanogel core (Figure 0.4) was confirmed via fluorescence, UV-Vis, and DLS analysis. 
Moreover, dual-sensitive LGs were non-toxic and preferentially underwent intracellular uptake, 
providing further evidence of their potential as a parenteral delivery vehicle. Comparison of non-
pH sensitive DOPC:CHOL LGs vs. DOPE:CHEMS LGs was also done to confirm their differences 
in pH-sensitivity in bulk solution along with varying cell uptake profile. The tunable core, shell, 
and guest molecules allowed for monitoring intracellular distribution of lipid, protein, and 
hydrophobic guest components both individually and in combination to provide insight of how 
LGs interact in vitro. Having explored the dual-encapsulation and dual-sensitivity character of the 
LGs, along with their ability to deliver intracellularly, we expanded the scope of LGs and polymer 
nanogels to determine their potential as oral delivery scaffolds. With that, we decided to look at 
modifications of the LG and polymer nanogel system for characterizing their stability under 
simulated oral administration conditions. 
1.4.4 Formulating lipid and polymer materials for oral delivery  
Characterizing oral delivery capabilities of nanomaterials is broken into two major 
groups, simulated gastrointestinal (GI) fluid stability and mucus/epithelial permeability. Within 
Lipogel (LG)
1st
stimuli
2nd
stimuli
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Chapter 4, we focused on establishing characterization of nanomaterial stability within GI fluids. 
Due to complexity of both GI fluids and LGs, we decided to characterize stability of simplified LG 
and amphiphilic polymer nanogel (ANG) components, as building blocks for future oral delivery 
scaffold design. Initial stability of a LS system in GI fluids was monitored, which will be later 
modified into an LG.  Such analyses highlighted the harshness of GI fluids and more importantly 
revealed the difficulty in characterizing both carrier and guest stability in GI fluids. Such results 
led to characterizing model hydrophobic guest stability in GI fluids. To do this, we decided to use 
a more established amphiphilic polymer nanogel (ANG) scaffold, which was also monitored for 
GI stability in comparison to LSs.73,74 Overall the complex nature of GI fluids makes characterizing 
nanomaterial stability a big challenge, although initial analysis of model guests along with LS and 
ANG stability in GI fluids have laid ground work for future design and characterization of LG and 
ANG scaffolds as oral delivery vehicles. 
1.4.5 Summary and future perspectives 
Overall this work was a culmination of formulating a new and tunable LG system, along 
with determining methods to characterize complex nanomaterials in solution. Through 
collaboration, we were able to establish new characterization methods, which are applicable 
beyond just LGs, with potential utility for characterizing other complex nanomaterials in 
solution. Looking at the summarized developments, there are an array of directions this work 
can go, which we highlighted within Chapter 5.  
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CHAPTER  2 
 
FORMATION AND CHARACTERIZATION OF LIPID COATED NANOGELS (LIPOGELS) FOR 
PROTEIN AND HYDROPHOBIC SMALL MOLECULE ENCAPSULATIONb 
2.1 Introduction 
The non-covalent interactions responsible for supramolecular nanoassemblies are 
comparable to the forces balancing natural supramolecular assemblies (i.e. proteins, DNA 
helices, lipid bilayers) in our bodies.75 Supramolecular assemblies are created through the 
combination and balance of different non-covalent interactions such as hydrogen bonding, 
aromatic acceptor-donor interactions, - interactions, hydrophobic interactions, van der Waals 
forces, metal chelation and electrostatics.75,76 Such interactions allow nanomaterial scaffolds to 
self-assemble and entrap therapeutics within a desired media (typically aqueous).  
2.1.1 Supramolecular scaffolds for dual-guest encapsulation  
Synthetic polymers capable of supramolecular self-assembly in aqueous media are 
typically amphiphilic copolymers, which can encapsulate hydrophilic or hydrophobic guests. 
Typically non-reactive self-assembling polymers are used for hydrophobic guest encapsulation, 
such as small molecule cancer therapeutics.77 Unlike non-reactive polymer self-assembly, which 
relies on intra and intermolecular polymer-polymer interactions, reactive self-assembly relies on 
intermolecular polymer-guest interactions for guest encapsulation, and subsequent assembly 
                                                                    
b Content of this chapter was adapted from published manuscripts: 
2 Homyak, C.; Anson, F.; Thayumanavan, S. In Comprehensive Supramolecular Chemistry II; 
Atwood, J. L., Ed.; Elsevier, 2017; Vol. 5, pp. 227–254. 
72 Homyak, C. C.; Fernandez, A.; Touve, M. A.; Zhao, B.; Anson, F.; Hardy, J. A.; Vachet, R. W.; 
Gianneschi, N. C.; Ross, J. L.; Thayumanavan, S. Lipogels for Encapsulation of Hydrophilic 
Proteins and Hydrophobic Small Molecules. Biomacromolecules 2017, acs.biomac.7b01300. 
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formation. Reactive self-assembly is typically used for hydrophilic biomolecule encapsulation 
through ionic interactions or covalent linkages of guest molecules to polymer chains. Despite 
biomolecule encapsulation via reactive self-assembly, there are great advantages in non-
covalent guest encapsulation of hydrophilic biomolecules within a hydrophilic polymer network. 
Polymers that cannot naturally self-assemble within aqueous solution, commonly hydrogels or 
natural polymers, typically require water-in-oil (w/o) type emulsion processes to assemble in 
water.78 This method has been successful for encapsulation of therapeutics, proteins, or 
monoclonal antibodies.50,79 However, set-backs to emulsion formation are the additional 
purification steps necessary along with the oil phase readily denaturing sensitive biomolecule 
guests.80 Beyond this, another large set-back to polymer nanomaterials is their inability to non-
covalently encapsulate multiple guest types (e.g. hydrophilic and hydrophobic), without 
extensive synthetic effort.  
A popular nontherapeutic scaffold which can both self-assemble and have dual-guest 
encapsulation are liposomes (LSs). LSs readily self-assemble into vesicles within aqueous 
medium. In addition to the ease of LS self-assembly, their morphology allows for sequestering 
both hydrophilic and hydrophobic guest molecules within its aqueous lumen and lipid bilayer 
shell respectively. The aqueous self-assembly, hydrophobic/hydrophilic guest encapsulation, 
and tunable properties (i.e. size, surface functionality, stimuli-sensitivity) make LSs 
advantageous carriers for multi-drug delivery. The breadth of knowledge on LSs and their 
enhanced biocompatibility has lead them to be a popular scaffold among clinically available 
nanotherapeutics, although as mentioned in Chapter 1, stability and release challenges exists 
with LSs. Lipid-polymer hybrid systems can be exploited to overcome assembly and stability 
setbacks typically observed with polymer or LSs respectively.   
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2.1.2 Lipogel scaffold for dual-guest encapsulation  
As discussed throughout Chapter 1, lipogels (LGs) are of recent interest due to their 
ability to trap hydrophilic and hydrophobic molecules  within their aqueous core and lipophilic 
shell, respectively.56,58,60,61,63–67,69,81 Recent efforts have reported LG systems for mono- or dual-
encapsulation56,70 of various hydrophobic small molecules67 and/or hydrophilic 
biomolecules.30,57,60 Such guest encapsulation is done through formation of LGs  through a one- 
or two-step process.61  In the two-step method, hydrophilic guest loaded polymer gels are initially 
formed, typically via oil-in-water emulsions and polymerized typically via radical polymerization 
(e.g. RAFT,71 UV-initiated70).  After purification, gels are then coated with a hydrophobic guest 
loaded lipid bilayer shell.69,70  In the one-step LG formation process, an aqueous self-assembling 
LS is used to simultaneously encapsulate polymer precursors and guests. The LS shell then acts 
as a template for polymerizing the precursors into a crosslinked gel core. Most commonly, core 
polymerization occurs via UV-initiated radical polymerization of acrylate/acrylamide30,57,59,65,67 or 
thiol-ene56,58 type moieties. Additionally, both hydrophilic (within the core) and hydrophobic 
(within lipid bilayer) guests can be non-covalently entrapped during this process.  Thus, one-step 
LG formation processes are more appealing due to their simplicity and complete aqueous self-
assembly.  
The array of LG formulations reported30,56–58,61,63–70,81 have shed light on methods used for 
particle-guest formation, purification and characterization.  Despite some common trends in 
formation and purification steps, the complex nature of dual-guest loaded core-shell LG systems 
makes their characterization a formidable challenge.  Establishing common characterization 
techniques, applicable to a diverse array of LG systems is necessary for comparing system-to-
system variations to develop a better fundamental understanding of LG materials. 
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Within this work we have displayed the formation and characterization of a new LG 
system using a single-pot methodology to entrap both hydrophilic protein and hydrophobic 
guest molecules within LS templates. Nanosized LGs (100-200 nm) are subsequently formed via 
UV irradiation of the polymer gel core, which we refer to as a nanogel throughout later sections 
of this work. (Figure 0.1) We have decided to use labeled lipids and model guest molecules for 
easy characterization via common techniques, allowing system translation for future 
combinations including therapeutic guests. To track the LG carrier, a rhodamine labeled 
phosphoethanolamine lipid (PE-RD) was utilized. In addition, green fluorescent protein (GFP), 
and hydrophobic dye probes (DiI and DiD) are used for modeling characterization of protein and 
hydrophobic small molecule guests, respectively. Using multicolor fluorescence detection and 
imaging, we are able to quantify the effectiveness of guest encapsulation within this LG 
formulation. This particular design is geared towards intracellular delivery via pH and redox 
sensitive characteristics, which is underway but will be not be discussed within this article. 
 
Figure 0.1Single-pot formation of dual-guest loaded LGs 
2.2 Experimental  
2.2.1 Materials  
Di(ethylene glycol) methyl ether methacrylate (DEGM), 2-Hydroxy-4′-(2-
hydroxyethoxy)-2-methylpropiophenone (PI), sodium-L-ascorbic acid (AA), sodium hydroxide 
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(NaOH), 1,1′-dioctadecyl-3,3,3′,3′-tetramethylindocarbocyanine perchlorate  (DiI), L-glutathione 
reduced (GSH), carbonic anhydrase (CA), and Triton X-100 (TX) were all purchased from Sigma 
Aldrich. 1,1'-dioctadecyl-3,3,3',3'-tetramethylindodicarbocyanine perchlorate (DiD) was 
purchased from ThermoFisher Scientific. Phospholipids and sterol; 1,2-dioleoyl-sn-glycero-3-
phosphoethanolamine (DOPE), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine 
rhodamine B sulfonyl) ammonium salt (PE-RD), 1,2-dioleoyl-sn-glycero-3-
phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] ammonium salt (PE-PEG), and 
cholesterol hemisuccinate (CHEMS) were purchased from Avanti Polar Lipids Inc. Enhanced 
green fluorescent protein (GFP) was kindly provided by our collaborator, Jeanne Hardy. All listed 
reagents obtained were used without further purification unless otherwise stated.   
2.2.2 Instrumental analysis   
Formation, purification, and analysis were performed in pH 7.4, 10 mM PBS buffer. 
Concentrations are reported with respect to lipid concentration unless otherwise noted. All size 
analysis was done using dynamic light scatting (DLS) on a Malvern Zetasizer Nano ZS. Bulk 
sample UV-visible (UV-Vis) absorption was monitored on a PerkinElmer Lambda 35 
Spectrometer, while sample fluorescence analysis was performed on a PerkinElmer LS 55 
Spectrometer.  
2.2.2.1 Cryogenic electron microscopy (CryoEM) analysis 
Cryogenic electron microscopy (CryoEM) grids were prepared by pipetting 4 µL of 
sample onto a Quantifoil R2/2 TEM grid that had previously been glow discharged using an 
Emitech K350 glow discharge unit and plasma-cleaned for 90 seconds in an E.A. Fischione 1020 
unit. The grids were blotted with filter paper under high humidity to create thin films, then rapidly 
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plunged into liquid ethane. The grids were stored under liquid nitrogen, then imaged on a FEI 
Tecnai G2 Sphera microscope operating at 200 keV. The samples were kept at ˂ -175 ºC while 
imaging. Micrographs were recorded on a 2k x 2k Gatan CCD camera. 
2.2.2.2 Matrix-assisted laser desorption ionization-mass spectrometry (MALDI-MS)  
Matrix-assisted laser desorption ionization-mass spectrometry (MALDI-MS) analysis 
was done on free CA and CA-LGs, which were digested and analyzed for the presence of CA 
peptide fragments. Sample digestion and MALDI-MS analysis was done following our previously 
reported protocol.50 In general, CA samples were prepared in 50 mM Tris buffer at pH 8.0.50 The 
stock solutions were denatured with 10 % acetonitrile at 55 ℃ for 15 mins. After samples were 
cooled down, immobilized trypsin was added and incubated at 37 ℃ for 15 h to finish digestions. 
Samples were then centrifuged at 14000 rcf to obtain the supernatant solution as the final CA 
protein digests solution. Digested samples were analyzed by MALDI-MS with a matrix solution 
of α-Cyano-4-hydroxycinnamic acid (CHCA) prepared at a concentration of 10 mg/mL in 50 μL 
ACN: 47.5 μL H2O: 2.5 μL TFA. MALDI-MS was analyzed on a Bruker Autoflex III time-of-flight 
mass spectrometer and a Bruker UltrafleXtreme MALDI-TOF/TOF mass spectrometer. All mass 
spectra were acquired in the reflectron mode with accelerating voltage of 19 kV. Each spectrum 
is the average of 500 laser shots at 50 % power.  
2.2.2.3 Total internal reflection fluorescence (TIRF) microscopy 
Total internal reflection fluorescence (TIRF) microscopy was performed in three colors to 
characterize individual LGs with RD-, GFP-, and/or DiD- (0.5 % loading). Samples were flowed 
into glass chambers made from a cover glass and slide treated under UV-Ozone for 20 minutes 
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and assembled into a flow chamber with double stick tape. Sample was diluted to 0.5 – 5 μM in 
order to observe physically separated LGs on the glass surface.  Free GFP was imaged at 0.01-0.1 
nM as a control to check imaging conditions and photobleaching of single fluorophores. LGs with 
GFP, RD and DiD signals were detected using 488, 532, and 638 nm wavelength lasers 
respectively. TIRF was performed on a home-built, multi-laser system constructed around a 
Nikon Ti-E inverted microscope, equipped with a 60x, 1.49 numerical aperture, oil-coupled 
objective (Nikon). An additional 4x or 2.5x magnifier was added to make the pixel size 67.5 
nm/pixel or 108 nm/pixel, respectively. Images of single LGs in each color were separately 
recorded using an Andor iXon Duo-648 EMCCD camera. Continuous imaging without shuttering 
was performed at exposure times of 300-500 ms for 5 minutes in order to photobleach the GFP 
signal. The number of GFP molecules in individual LGs was determined by analyzing the GFP 
intensity over time using the ImageJ software, which is described in detail in section 0 below.82  
2.2.3 Crosslinker synthesis  
 
Scheme 0.1: Crosslinker synthesis 
Crosslinker N,N’-bis(methacryloyl)-L-cystine was prepared using a previously reported 
procedure.83 L-cystine and methacryloyl chloride, were purchased from Sigma Aldrich and used 
without additional purification. To a solution of L-cystine (4.0 g, 16.6 mmol) and NaCO3 (3.53 g, 
33.3 mmol) and DI water was added NaOH pellets until reagents fully dissolved. Reaction mixture 
was cooled to 0°C and methacryloyl chloride (4.8 mL, 50 mmol) was added dropwise. The 
reaction was stirred for 4 h maintaining pH 8-9 with additional NaOH as needed. Concentrated 
HCl was then added until mixture pH ~2.  The product was extracted with ethyl acetate (3 X) and 
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dried over MgSO4. Extract was concentrated in vacuo and precipitated in ethyl ether to yield the 
product (4.70 g, 75 %) as a white solid (Scheme 0.1). 1H NMR (400 MHz) and 13C NMR (100 MHz) 
spectra were recorded on a Bruker NMR spectrometer using residual proton resonance of the 
solvent as the internal standard. Chemical shifts are reported in parts per million (ppm).  1H NMR 
(400 MHz, MeOD) δ 5.79 (s, 1H), 5.45 (s, 1H), 4.80 (q, 1H), 3.37 (m, 1H), 3.10 (m, 1H), 1.98 (s, 3H) 
ppm; HRMS (FAB+) calcd. for C14H22N2O6S2 (M+H) 377.076, found 377.085. (Scheme 0.1) 
2.2.4 Liposome (LS) formation 
Liposome (LS) formation was done with a total lipid concentration of 2.5 mM, respective 
to the hydration volume. Lipid composition contained 1% PE-PEG (0.070 mg, 0.025 μmol) with 
DOPE:CHEMS at a ratio of 60:40 respectively [DOPE (1.1 mg, 1.5 μmol) and CHEMS (0.49 mg, 
1.0 μmol). Rhodamine (RD) labeled LSs contained additional .025% PE-RD (0.00081 mg, 0.00063 
μmol) to the above lipid mixtures. Lipid and sterol components were mixed in chloroform and 
vortexed before removing CHCl3 under an argon stream and dried under vacuum overnight. 
Dried lipid films were then hydrated with 1 mL PBS or polymer precursor hydrant (described 
below) at 2-8 °C for 3 hours; vortexing initially and every hour throughout the hydration period. 
Following hydration, LSs were extruded 21 times through a polycarbonate membrane (100 nm 
19 mm) using a mini-extruder set (Avanti Polar Lipids Inc.). Crude LSs (cLS) were either directly 
converted into lipogels (described below), or purified via dialysis (biotech cellulose ester 
membrane MWCO 300 KDa, Spectrum Labs) in PBS at 2-8 °C.  
2.2.5 Lipogel (LG) formation 
Lipogel (LG) formation utilized the lipid films described above, which were hydrated with 
a 5 % (w/v) (50 mg/mL) polymer precursor solution containing 95 % monomer (DEGM) and 5 % 
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crosslinker (N,N’-bis(methacryloyl)-L-cystine (CDM)). Crosslinker amount coincided with 
previous reports exhibiting 5 % crosslinker being optimal for accommodating a protein similar in 
size to GFP.57 Polymer precursor solutions were made by mixing DEGM (44 μL, 125 μmol), CDM 
(5 mg, 6.6 μmol), PI (0.2 mg, 0.9 μmol), NaOH (50 μL, 1 M), and PBS (0.5 mL) followed by 
sonication to fully disperse reagents. Dispersed mixtures were diluted with additional PBS buffer 
(0.5 mL) or hydrophilic guest stock. For protein containing LGs, either GFP (0.5mL, 100 μM) or 
CA (0.5mL, 100 μM) was added in place of the PBS buffer dilution. Precursor and protein solutions 
were used to hydrate and extrude lipid films as described in the LS formation section above. After 
extrusion, solutions were mixed with photo-inhibitor, ascorbic acid (AA) (200 mol % with respect 
to PI), to prevent polymerization from occurring outside of LSs.59,67 Immediately after adding AA, 
samples were exposed to UV light (365 nm) for 30 min, followed by syringe filtering (0.45 μm pore 
size) to yield the crude lipogel (cLG). For samples with hydrophobic cargo loading, DiI or DiD (0.5 
or 10 mol % with respect to lipid) in acetone was added to cLGs. Samples stirred overnight at 2-
8 °C and syringe filtered before purification. All cLSs and cLGs were purified via dialysis (biotech 
cellulose ester membrane MWCO 300 KDa, Spectrum Labs) in PBS buffer at 2-8 °C for at least 24 
h. Purified liposome (LS) and lipogel (LG) samples were stored at 2-8 °C until further use. Size 
analysis was done for all LSs and LGs (50 μM) both initially and after lipid shell removal with TX 
(100 mol % with respect to lipid) to confirm core crosslinking.  
2.2.6 Bare nanogel purification 
Bare nanogel (NG) was obtained from cLGs. The lipid shell was removed with TX (100 
mol % with respect to lipid) at room temperature for 1-2 h. TX-lipid (TX-L) mixed micelles were 
then removed via dialysis in PBS (biotech cellulose ester membrane MWCO 100 KDa, Spectrum 
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Labs) for 48 h, to yield the NG. Size and fluorescence were monitored throughout the purification 
to confirm removal of lipid micelles from bare NG core. 
2.2.7 Hydrophobic guest quantification 
Hydrophobic guest quantification was done by UV-Vis analysis in acetone. Purified DiI-
LGs and DiD-LGs were diluted to a final concentration of 50 μM lipid in acetone and syringe 
filtered (0.45 μm pore size) before checking the absorption. Extracted DiI and DiD in acetone 
were quantified at λmax absorbance of 549 and 645 nm respectively.  
Encapsulated dye (M1) was calculated using extinction coefficients at λmax values of 549 
and 645 nm from standard curve calibrations of DiI and DiD (Figure 0.2). Encapsulation efficiency 
(% EE) was then determined using encapsulated DiI/DiD concentration (M1) with respect to initial 
concentration (M0) of DiI/DiD loaded. Loading efficiency was calculated using M1 with respect to 
total lipid concentration (Mlipid) 
% 𝐸𝐸 =
𝑀1 
𝑀0 
× 100  
% 𝐿𝐸 =
𝑀1 
𝑀𝑙𝑖𝑝𝑖𝑑 
× 100 
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Figure 0.2  Standard curves of (a) DiI at λmax 549 nm and (b) DiD  at λmax 645 nm 
2.2.8 Quantification of protein via bulk fluorescence  
Purified GFP-LGs were diluted to a final concentration of 100 μM lipid in PBS to monitor 
bulk fluorescence and DLS size distribution. Fluorescence emission monitored for samples and 
standards at an excitation of 480 nm and scanning speed of 500 nm/min. A linear fit calibration 
curve of free GFP was made at λmax emission of 522 nm for calculating GFP encapsulation in GFP-
LGs. (Figure 0.3) 
 
Figure 0.3 (a) Fluorescence standard curve for free GFP at λmax 522 nm and (b) DLS of GFP-LG 
The number of lipids per lipogel (Ntot) and subsequent number of lipogels per mL (Nlipo) 
was calculated via previously reported methods based on size, composition, and concentration 
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of lipid.84  Average lipid molecule surface area (a) was calculated using reported surface areas for 
DOPE (aDOPE =  64 Å2)85, CHOL (aCHOL = 41 Å2)86, and PE-PEG (aPE-PEG = 184 Å2)87 along with their 
molar ratios, NDOPE (0.6), NCHOL (0.4), and NPE-PEG (0.01).  
𝑎 = 𝑎𝐷𝑂𝑃𝐸𝑁𝐷𝑂𝑃𝐸 + 𝑎𝐶𝐻𝑂𝐿𝑁𝐶𝐻𝑂𝐿 + 𝑎𝑃𝐸−𝑃𝐸𝐺𝑁𝑃𝐸−𝑃𝐸𝐺  
The number of lipids per lipogel (Ntot) was calculated using a in combination with 
previously reported84 lipid bilayer thickness (h) of 5 nm and lipogel radius (r) determined from 
DLS analysis.  
Ntot =
[4𝜋𝑟2 +  4𝜋(𝑟 − ℎ)2]
𝑎
 
Ntot along with lipid concentration (Mlipid)) and Avogadro’s Number (Na = 6.02E23) were 
then used to calculate the number of lipogels per mL of sample (Nlipo).  
𝑁𝑙𝑖𝑝𝑜 =
[𝑀𝑙𝑖𝑝𝑖𝑑 × 𝑁𝑎 ]
[𝑁𝑡𝑜𝑡  × 1000]
 
Similarly, molarity of GFP within LGs (determined from fluorimetry) was converted into 
total number of GFP molecules per mL of sample (NGFP) using Avogadro’s Number.  
𝑁𝐺𝐹𝑃 =
[𝑀𝐺𝐹𝑃 × 𝑁𝑎 ]
1000
 
Finally, the number of GFP molecules per lipogel (NGFP/liipo) was determined with NGFP and 
Nlipo.  
𝑁𝐺𝐹𝑃/𝑙𝑖𝑝𝑜 =
𝑁𝐺𝐹𝑃
𝑁𝑙𝑖𝑝𝑜
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Table 0.1 GFP quantifications with LG size distribution 
diameter (nm) Ntot Nlipo NGFP/mL NGFP/lipo 
59 32386 1.9E+12 4.3E+12 2 
68 44446 1.4E+12 4.3E+12 3 
79 60696 9.9E+11 4.3E+12 4 
91 82896 7.3E+11 4.3E+12 6 
106 113439 5.3E+11 4.3E+12 8 
122 152132 4.0E+11 4.3E+12 11 
142 208485 2.9E+11 4.3E+12 15 
164 280724 2.1E+11 4.3E+12 20 
 
2.2.9 Quantification of protein via TIRF 
Quantification of GFP in single lipogel particles was performed through photobleaching 
via TIRF, as previously described.82 Samples of GFP-loaded lipogels were adhered to clean glass 
chambers and illuminated with lasers, as described in the main text. Photobleaching was 
performed from continuous imaging of samples without shuttering at exposure times of 300-500 
ms. Fiji/ImageJ was used for image analysis. First, timelapse movies of fluorescence were 
corrected for lateral drift using the StackReg plugin.  
Next, we needed to make a mask to determine the location of the particles for analysis. 
We did this by created a standard deviation Z projection image of the time lapse images. This 
highlights any molecule that was bright and then went dark, since the standard deviation of 
those pixels is high over time. Standard deviation images were inverted and thresholded to 
detect black particles on a white background (a binary image). The analyze particles command 
was used to create a mask of particles by detecting particles that were 5-30 pixels2 in size, and 0-
1 in circularity. Particles on edges were excluded. The mask identified the location of each 
particle, called the “recording starts” in ImageJ. The binary image of the particles was processed 
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to expand (dilate) and separate (watershed) particles. This final image was the binary mask for 
analysis of individual particles. 
Using the region of interest (ROI) manager and particle locations recorded from the 
mask, these same ROIs could be used on the movie data files to analyze the intensity of the 
individual LGs over time. The continuous movie data was corrected by background subtraction 
using the rolling ball method (radius 50 pixels) in Fiji. Next, the multi-measure plugin was used 
with recorded particle locations (from the mask) to determine individual particle mean intensities 
over time on background subtracted images. The text data was imported into a spreadsheet 
manager and the intensity of each location was plotted over time. We performed this analysis on 
45-50 spots per free GFP or LG sample.  
From the plots of intensity vs. time, we determined the average intensity of a single GFP 
photobleaching step, <I1,GFP>, using free GFP or individual detectable photobleaching steps in the 
LG intensity trace (Figure  7a, main text). This <I,1GFP > was used to back calculate the number of 
GFPs in a single LG, NGFP, by taking the ratio of the initial intensity of LG, I0,LG, and dividing by 
<I1,GFP>: 
	
N
GFP
=
I
0,LG
I
1,GFP
 
The number of GFPs in each LG was similar whether we used single free GFP steps or 
internal bleach steps within LGs as the basis for <I1,GFP>. The distribution of the number of GFPs 
within the LGs is shown in the main text compared to the bulk analysis (Figure 0.13). 
2.2.10 LG stability via Förster resonance energy transfer (FRET)  
Förster Resonance Energy Transfer (FRET) stability was used to monitor lipid shell 
stability. LGs loaded with either 10 mol % DiI (DiI-LG) or 10 mol % DiD (DiD-LG) were mixed in a 
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1:1 ratio with a final LG concentration of 1-2 mM. Aliquots of the mixture were removed and 
diluted to 25-50 μM in PBS for each UV-Vis and fluorescence reading over a 24 h period. FRET of 
donor (DiI) and acceptor (DiD) emissions was monitored after an excitation of 480 nm. DLS of 
cLG and LG samples was also checked with and without TX to ensure LG size and core 
crosslinking was unaffected. 
2.3 Results and discussion 
2.3.1 Confirming LS, LG, and NG formation 
Single-pot LG formation was done using LS templates composed of DOPE and CHEMS 
with a small amount of poly(ethylene glycol) (PEG) functionalized lipid (PE-PEG), which 
is known to enhance LS stability and biocompatibility.88  In order to track the lipid shell 
of LGs a small amount of rhodamine-labeled lipid, PE-RD, was added to specific LS and 
LG samples (Figure 0.4-right). Initial preparation was done through hydration of dried 
lipid films with an aqueous polymer precursor solution containing 95% monomer 
(DEGM) and 5% crosslinker (CDM) along with photoinitiator.  Protein loading was 
accomplished by adding either GFP or CA to the polymer precursor solution prior to lipid 
hydration (Figure 0.4-left).  Following LS hydration, extrusion was done to aid in polymer 
precursor and protein encapsulation, as well as to ensure monodisperse sizing of LS 
templates (cLS).  The nanogel core was then polymerized within cLSs using UV 
irradiation to form crude lipogels (cLGs).   Similar to reported methods, a photo-inhibitor, 
AA, was added before UV exposure, which prevented polymerization from occurring 
outside of LS templates.59,67  After polymer core crosslinking, cLGs were loaded with 
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hydrophobic guest molecules, DiI or DiD.  Upon mixing with aqueous LGs DiI and DiD 
became soluble, which confirmed they were being sequestered within the hydrophobic 
lipid bilayer shell.  All cLSs and cLGs were purified via dialysis to remove any un-
encapsulated small molecules or proteins.  
 
Figure 0.4 Lipogel (LG) molecular design for (left) polymer core and (right) lipid shell  
Liposome (LS) templating was characterized via size comparisons of the monomer 
encapsulated cLSs vs. subsequent polymer crosslinked cLGs. Size similarity between cLS and 
cLG verified the LS shell acted as a template for the polymer core and no polymer crosslinking 
occurred outside of the LS template. Nanogel core crosslinking was confirmed after lipid shell 
displacement of cLS and cLG samples with TX. When adding TX to cLSs, displacement of lipid 
occurred to form TX-L mixed micelles (~10 nm). However, when TX is added to cLGs, TX-L mixed 
micelles (~10 nm) are present along with the crosslinked NG core (~150 nm). (Figure 0.5)  
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Figure 0.5  DLS before and after TX addition of crude (a) liposome (cLS) vs. (b) lipogel (cLG). 
To obtain the bare nanogel (NG), TX was used to displace the lipid shell of crude LGs. 
After TX lipid shell displacement of the crude rhodamine labeled LG (cRD-LG), TX-L mixed 
micelles were successfully removed from the sample (TX – cRD-LG) via dialysis to obtain the NG. 
Size was monitored to confirm removal of TX-L micelles (~10 nm) and the remaining NG core 
(~150-200 nm). Due to excess TX addition, majority of DLS plots throughout this work are shown 
in % intensity vs. diameter size (nm). However, comparison of all DLS plots (% intensity, volume, 
and number) for cRD-LG, TX - cRD-LG, and NG was used as additional means to confirm NG 
purification. Due to the large amount of TX needed to displace the liposome within the % volume 
and number DLS plots, only TX-lipid mixed micelles are present (dashed line). Disappearance of 
the TX-lipid mixed micelle size with subsequent reappearance of the nanogel size (purple) further 
confirmed TX-lipid mixed micelles were fully removed from the bare NG. The pure NG displayed 
similar size to its parent LG sample, further confirming the lipid shell dictated the NG core size. 
Fluorescence was also used to confirm lipid removal and NG purification. Results showed initial 
fluorescence of RD labeled lipid and subsequent loss of signal after NG purification. Such loss of 
RD signal in NGs confirmed the lipid shell was fully removed from the solution (Figure 0.6)  
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Figure 0.6 Characterization of NG purification via DLS % (a) intensity (b) volume and (c) number 
plots along with (d) bulk fluorescence  
Morphologies of LS, LG, and NG were characterized by CryoEM. Images of LS, LG, and 
NG samples showed similar size dispersion as DLS results. Both LS and LG samples displayed 
lipid shell coating, while the NGs existed primarily as polymer aggregates, without a lipid shell. 
Morphology differences between LS/LG and NG was additional confirmation that the lipid shell 
was removed from LGs. Further analysis of the LS and LG samples confirmed they had 
unilamellar lipid shell morphology with minimal changes in morphology before and after UV 
crosslinking. (Figure 0.7) 
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Figure 0.7 CryoEM of (left) LS, (middle) LG, and (right) NG  
2.3.2 Verifying LG purification 
Typically centrifuge filtration30, chromatography,67 or dialysis56,57,65 methods are used for 
purifying LGs. Despite this array of purification techniques, few reports confirm the final purity 
of LGs to reassure guest molecules were indeed encapsulated inside LGs and not free in solution. 
Since proteins can be entrapped within, but also remain free in the solution after LS formation, 
it was crucial to confirm removal of un-encapsulated protein, and more importantly, to verify 
that the only remaining protein was trapped within the LGs. Some reports confirm free protein 
removal and subsequent encapsulation with enzyme activity57 or protein quantitification56 assays 
of LG variations. Due to substrate specificity of activity assays and LS turbidity interference with 
absorbance based quantification assays, it was advantageous to explore additional methods for 
characterizing LG purity and protein encapsulation. Herein, we decided to use two different 
NGLGLS
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techniques for such characterization, applicable to an array of fluorescently labeled or enzyme 
digestible guests, via fluorescence microscopy or mass spectrometry respectively. 
 Total internal reflection (TIR) of light occurs when the angle of incidence of a light ray is 
greater than the critical angle respective to the interface between materials of low and high 
refractive index, such as water and glass.89 In TIR, a laser beam is reflected at the cover glass – 
water interface to form an evanescent wave of light that penetrates the sample for only 100 – 
300 nm. This allows materials adhered to the cover glass surface to be easily detected with 
minimal background signal interferance.89 Since individual fluorophores are visible on the 
surface, TIRF microscopy allows visualization of free guest molecules even at parts per billion 
(nM) concentrations. Using TIRF, we monitored the purity of the LGs through direct visualization 
of rhodamine labeled LG (RD-LG, 532 nm) and guest protein (GFP, 488 nm). Prior to dialysis 
purification, the crude GFP loaded RD-LG (cGFP-RD-LG), had excess GFP signal in comparison 
to the RD-LG signal (Figure 0.8-top). After purification, excess GFP was removed and remaining 
GFP and RD signals were primarily colocalized, respective to individual GFP-RD-LGs (Figure 0.8-
bottom). Additional analysis of GFP photobleaching was also done with TIRF to quantify protein 
encapsulation, which is discussed in more detail below. Beyond TIRF, MALDI-MS was also used 
to verify removal of free protein from pure LGs.  
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Figure 0.8  TIRF characterization of (top) crude LG vs. (bottom) pure LG  
MALDI-MS detection of proteins within polymer nanogel solutions was previously 
established within our group.50 In brief, free or exposed (on exterior of nanoparticle) proteins are 
subject to digestions via trypsin, a serine protease. If digested proteins are above femtomolar 
concentrations, their subsequent peptide fragments are detectable by MALDI-MS. Alternatively, 
if proteins are completely entrapped within the polymer nanoparticle, they will not be subject to 
trypsin digestion and in return have negligible detection on MALDI-MS. For our studies, carbonic 
anhydrase (CA) was used in place of GFP for such analysis due to CA’s similar size to GFP, but 
better digestibility. Free CA along with CA loaded purified LG (CA-LG) were digested with trypsin 
for MALDI-MS peptide fragment analysis. Results revealed peptide fragments corresponding to 
free CA were negligible (or below femtomolar concentration) within CA-LGs. Based on results of 
MALDI-MS and TIRF analysis, we believe free protein was successfully removed after dialysis 
purification, and the remaining protein is encapsulated within LGs. (Figure 0.9) 
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Figure 0.9  MALDI-MS analysis of (top) free CA, (middle) CA-LG, and (bottom) empty LG 
In addition to free GFP removal, TIRF was also used to verify dual-guest encapsulation 
within LGs. Similar to the GFP-RD-LG, the purified DiD loaded GFP-RD-LG (DiD-GFP-RD-LG) 
displayed signal for the lipid (RD, 532 nm), protein (GFP, 488 nm), and hydrophobic guest (DiD, 
638 nm). Colocalization of individual-RD, GFP, and DiD signals within the composite overlay 
verified both protein and hydrophobic guest were indeed within LGs (Figure 0.10a). Guest 
encapsulation and subsequent quantification was further confirmed using UV-Vis spectroscopy 
and fluorimetry of bulk samples. 
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Figure 0.10 TIRF of DiD-GFP-RD-LG to monitor loading of GFP and DiD within RD-LGs  
2.3.3 Quantification of hydrophobic guest 
Quantification of hydrophobic guest within the lipid membrane was done by UV-Vis 
absorption analysis of DiI-LG and DiD-LG samples (Figure 0.11). Due to poor solubility of 
hydrophobic guests in water, UV-Vis quantification was done in acetone for DiI/DiD-LGs and 
DiI/DiD standard solutions. The amount of DiI and DiD within LGs was quantified using extinction 
coefficients at λmax values of 549 and 645 nm, respectively (Figure 0.2). Encapsulation efficiencies 
of guest amounts in relation to initial amount of guest loaded was 66  5 % and 55  4 % for DiI 
and DiD respectively. Loading efficiency for the amount of guest encapsulated in relation to total 
lipid concentration was 7  1 % and 6  <1 % for DiI and DiD respectively. Due to interference 
from LG turbidity, similar UV-Vis analysis was not reliable for GFP quantification. Instead, we 
were able to quantify GFP using two other methods based around bulk fluorescence and single 
particle TIRF.  
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Figure 0.11 UV-Vis spectra of (a) DiI-LG and (b) DiD-LG to quantify hydrophobic guest 
encapsulation 
2.3.4 Fluorescence quantification of GFP 
Quantification of GFP via bulk fluorescence emission of GFP-LGs was more feasible due 
to minimal fluorescence interference from LG turbidity. Relative molarity of GFP (MGFP) within 
GFP-LGs was found using a linear standard curve monitoring emission λmax of 522 nm after 480 
nm excitation (Figure 0.3). Calculated MGFP, was then used in combination with DLS size 
distribution, and lipid concentration to determine the number of GFPs per mL of sample 
(NGFP/lipo). Plotting the NGFP/lipo with respect to % number of LGs (determined from DLS results) 
gave the NGFP/lipo distribution, revealing NGFP/lipo of ~4-5 being the most abundant (Figure 0.12). To 
verify the accuracy of this bulk fluorescence quantification method, we also used single particle 
TIRF to quantify NGFP/lipo for individual LGs. 
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Figure 0.12 (a) Bulk fluorescence of GFP-LG (b) distribution of # GFPs per LG  
2.3.5 GFP quantification via TIRF microscopy  
Additional quantification of GFP inside individual LGs was done by GFP photobleaching 
in TIRF microscopy using the 488 nm laser.82 Individual LGs are diffraction limited in fluorescence 
imaging, but the fluorescence intensity reveals the number of fluorophores in a diffraction-
limited region as long as the intensity falls within the linear range of the detector. We also used 
purified, single GFP molecules as a control and internal calibration standard. GFP molecules and 
LGs were imaged continuously over time. Analysis of the intensity of individual fluorescent spots 
displayed significantly different photobleaching patterns for free GFP and GFP-LGs. As 
expected, free GFP spots had single-step photobleaching patterns. Alternatively, GFP-LG spots 
(of the same size as free GFP) had a higher initial fluorescence intensity which decayed via a 
multi-step GFP photobleaching pattern, implying that there were multiple GFP molecules in each 
LG (Figure 0.13a). Photobleaching patterns for individual spots within GFP-LG samples were 
analyzed to determine NGFP/lipo. The distribution of NGFP/lipo was compiled from individual GFP-LG 
spot analyses. In agreement with fluorescence quantification, TIRF quantification revealed 
NGFP/lipo of ~4-5 being the most abundant overall (Figure 0.13b). Similarities in NGFP/lipo distribution 
for fluorescence and TIRF quantification methods validated the utility of these two quantification 
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methods. In addition to monitoring guest encapsulation and quantification, we also established 
methods to easily monitor LG shell stability.  
 
Figure 0.13 (a) TIRF photobleaching of free GFP vs. GFP-LG and (b) # GFPs per LG distribution  
2.3.6 Monitoring lipogel solution stability 
Lipid shell stability of LGs was monitored by tracking hydrophobic guest exchange over 
time. By using LGs loaded with either fluorescent donor (DiI) or acceptor (DiD) molecules their 
exchange over time could be monitored via FRET. When DiI and DiD come in close proximity 
FRET occurs, which implies leakage from one lipid shell to another. If the DiI and DiD guests are 
stably encapsulated within the lipid shell, then there should be no FRET detected. DiI-LG and 
DiD-LG samples were made separately and then mixed to monitor any change in FRET ratio. 
Analysis of this was done by plotting FRET ratio Ia/(Id + Ia) vs. time, where Ia and Id are the 
maximum emission intensity of the acceptor (DiD) and the donor (DiI) at 681 and 582 nm, 
respectively, measured separately. With all FRET analyses, the UV-Vis absorption was also 
monitored to confirm guest molecule concentration remained the same despite changes in FRET 
ratio. Full fluorescence and UV-Vis spectra for all FRET analyses can be referred to within 
Appendix A. 
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Initial fluorescence analysis of crude LG (cLG) and pure LG (LG) samples revealed they 
had significantly different lipid shell stabilities (Figure 0.14a). Minimal to no FRET exchange over 
time was detected with LGs, which reassured that LGs maintain stably encapsulated 
hydrophobic guests in solution. Interestingly, cLGs, which contain polymer precursors, displayed 
an opposite FRET ratio trend over time (Figure 0.14b). Despite the increasing FRET ratio, 
hydrophobic guest absorption was maintained over time (Appendix A). This was further 
reassurance that the lipid shell was still present in cLGs, although not stable enough to fully trap 
hydrophobic guest molecules. Additional DLS analysis of cLGs and LGs confirmed that particle 
size and core crosslinking were also unaffected, despite differences in lipid destabilization 
(Appendix A).  
 
Figure 0.14 (a) Fluorescence of cLG and (b) FRET ratio over time of cLGs and pure LGs  
To determine the cause of instability within the cLGs, an additional FRET analysis was 
performed after re-introducing monomer and crosslinker into purified LGs (LG + MC). The 
resulting FRET ratio was increased in comparison to the pure LG, which verified that small 
molecule polymer precursors were causing lipid shell instability (Figure 0.15). Full fluorescence 
and UV-Vis spectra for this FRET analyses can be referred to within Appendix A. Overall FRET 
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results revealed that the lipid shell of LGs is significantly stabilized after dialysis purification, and 
additional analysis of LG size after storage was additional verification of this stability.  
 
Figure 0.15 FRET ratio over time of LG vs. LG + MC  
To determine potential shelf-life stability of LGs the size and core crosslinking of LGs 
were checked again after 3 months storage at 2-8 °C. Both LG size and core crosslinking were 
well maintained after 3 months of storage, which further verified the solution stability of these 
LGs (Figure 0.16).  
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Figure 0.16: LG size and core crosslinking after 3 months storage at 2-8 °C (left) before and 
(right) after TX lipid displacement 
2.4 Conclusion 
In this work, we established a single-pot method for the formation of dual-guest loaded 
LGs.  A number of characterization techniques have been established to analyze these LGs, from 
their initial formation to final stability analysis.  All these techniques have applicability with a 
variety of LG systems containing diverse lipid, protein, and/or hydrophobic small molecule 
components. Initial formation was characterized by DLS before and after lipid shell 
displacement. Purification of LGs was monitored using TIRF and MALDI-MS to ensure full 
removal of any un-encapsulated guest molecules. Hydrophobic guest quantification was 
executed via UV-visible absorption spectroscopy, while protein encapsulation was quantified 
using bulk fluorimetry and single particle TIRF analyses. Monitoring FRET of mixed LGs over 
time, along with size analysis after 3 months confirmed these LGs have excellent solution 
stability after purification.  Overall, the dual-guest encapsulation, stability, and tunable nature of 
this LG system hold great applicability within biological or therapeutic delivery applications.  
Initial results reported here were pursued in more detail within Chapter 3 to understand stimuli-
sensitive characteristics of these LGs along with their viability under more biologically relevant 
conditions.  
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CHAPTER 3 
 
DUAL-RESPONSIVE LIPOGELS FOR INTRACELLULAR DELIVERY OF PROTEINS AND 
SMALL MOLECULESc 
3.1 Introduction 
Beyond confirming if LGs can dual-encapsulate guests, we wanted to characterize their 
dual-stimuli-sensitive character. As discussed in Chapter 1, there is benefit in selectively releasing 
therapeutic cargo under specific biologically relevant stimuli. Additionally, it is crucial to ensure 
these materials are inherently non-toxic in addition to seeing how they interact with tissues in 
vitro. Throughout this chapter we show bulk solution sensitivity and in vitro characterization of 
our pH- and redox- sensitive LG system, geared towards intracellular delivery. Typically, 
parenteral administration is used for initial analysis of nanotherapeutic efficacy. Understanding 
the biological barriers to parenteral administration and intracellular uptake pathways along with 
common lipid/polymer materials used to overcome them was key in this LG design.  
3.1.1 Barriers to parenteral delivery and intracellular uptake 
Parenteral administration can avoid many physiological barriers for therapeutic delivery, 
although it is necessary that materials and therapeutics are both sterile and free of 
microorganisms to avoid immune response after injection.90 Key routes for parenteral delivery 
are via intravenous, intramuscular, and subcutaneous administration. Intravenous (IV) delivery 
administers therapeutics directly into the blood circulation.90 A large benefit of this is bypassing 
tissue and vasculature barriers for therapeutics to reach bloodstream. More importantly IV 
                                                                    
c Content of this chapter was adapted from published manuscript: 
2 Homyak, C.; Anson, F.; Thayumanavan, S. In Comprehensive Supramolecular Chemistry II; 
Atwood, J. L., Ed.; Elsevier, 2017; Vol. 5, pp. 227–254. 
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delivery directs therapeutics to the heart and tissues prior to liver metabolism.90 Many new 
chemical entities (NME) are initially explored utilizing IV administration to monitor the 
pharmacodynamics (PD) and pharmacokinetics (PK) of therapeutics, along with the adsorption, 
distribution, metabolism, excretion, and toxicity (ADMET) profile of particles in circulation.90 Due 
to this reason, the vast majority of nanomedicines clinically approved by the Food and Drug 
Administration (FDA) utilize parenteral administration.18  
3.1.1.1 Intracellular uptake barriers  
After administration, nanomaterials must be able to enter the cell to have therapeutic 
effect. With this in mind, it is important to understand how nanomaterials can enter and 
distribute throughout cell compartments. Recent work has focused on both extracellular and 
sub-cellular organelle targeting of nanotherapeutics.7,8,91,92 Throughout this section we have 
highlighted the endocytosis pathways, which nanomaterials can selectively target and breach 
respectively.  
Endocytosis is the process where cell membranes undergo invagination; engulfing 
receptor bound membrane interacting molecules within an intracellular vesicle or endosome. 
Pathways that endosomes follow are largely dependent on signaling cascades triggered by the 
specific ligand-receptor interactions. Endocytosis is broken down into phagocytosis and 
pinocytosis. For a more extensive discussion of these processes, the reader is referred to the 
following literature.7,8,20,36 Depending on the endocytosis pathway, materials are engulfed within 
intracellular vesicles, and typically convert into early and late endosomes. (Figure 0.1) Early and 
late endosomes have decreased pH of 6-6.5 and 5.0-6.5 repectively.36,93 Small molecules released 
within the endosome can diffuse through the endosome membrane, however membrane 
destabilization is needed for complete endosomal escape of nanomaterials. Acidic pH within the 
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endosome can be exploited utilizing pH-sensitive amine or cationic functionalized materials, to 
enhance endosomal escape. Protonation of amine functionalized materials neutralizes the 
endosomal lumen, causing swelling and release of endosomal contents.36 When utilizing pH-
sensitive polymers for endosomal escape, it important to also account for the decreased 
extracellular pH of tumors around 6.2-6.9.36 Once nanotherapeutics have reached the cytosol, 
they can then target their desired subcellular organelle, or release desired cargo within the 
cytosol. As described in Chapter 1, redox-sensitive materials are commonly utilized for cytosolic 
release of therapeutics due to the increased GSH concentrations within cells vs. blood circulation.  
Late endosomes will eventually reach lysosome compartments, which have an even 
lower pH of ~4.5-5.0.93 Both the acidic and enzyme rich conditions within lysosomes have been 
exploited for nanotherapeutic7,8,36,37,49,94,95 and drug conjugate93,96–98 delivery. Lysosomes are 
fairly easy to target in comparison to other sub-cellular organelles due to many endocytosis 
pathways directing towards lysosomes. Various polymers with either ionizable functionality (e.g. 
carboxylic acid, amine) or acid cleavable units (e.g. acetal, hydrazone) are utilized for lysosomal 
disruption or release respectively. Selective delivery to the lysosome holds great potential for 
treating lysosomal disorders, which are currently treated with excessive amounts of enzyme 
replacement therapy.99 Combining polymer carriers49,94 and targeting molecules8 to protect and 
actively deliver enzymes to the lysosome holds great potential in surpassing current enzyme 
replacement therapy. Nanoparticles typically undergo pinocytotic pathways such as 
macropinocytosis, clathrin-mediated, and/or caveolin-mediated uptake. The similarities 
between various pinocytotic pathways allows for materials to simultaneously undergo different 
endocytosis pathways. With this, it is clear that extensive monitoring of nanoparticle cell 
trafficking via cell labeling,7 must be done to confirm the precise mechanisms of nanoparticle 
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cell-uptake. Many efforts have been focused on understanding modes of targeting specific sub-
cellular organelles, although this was beyond the scope of this work.8 (Figure 0.1) 
 
Figure 0.1 Intracellular uptake pathways for nanomaterials 
3.1.2 Stimuli-sensitive LG materials for intracellular delivery 
pH-sensitivity can be introduced to LSs by using pH-sensitive cationic phospholipids 
paired with anionic sterols. A well-known pH-sensitive LS system uses 1,2-dioleoyl-sn-glycero-3-
phosphoethanolamine (DOPE), paired with an anionic cholesterol hemisuccinate (CHEMS). 
Electrostatic repulsion between the carboxylate group on CHEMS and phosphate group on 
DOPE at neutral pH enhances lipid bilayer packing and LS stability, although this is greatly 
destabilized at acidic pH.100 Such lipid destabilization along with CHEMS having a high capacity 
to promote membrane fusion, makes DOPE and CHEMS an ideal combination for intracellular 
delivery.42 Many research efforts have confirmed DOPE:CHEMS LSs readily undergo intracellular 
uptake from destabilization within acidic endocytosis compartments (early-late endosome (pH 
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5.0-6.5), lysosome (pH 4.5-5.0).36,42,43,88,93,101 As mentioned in Chapter 1, LSs typically need to be 
functionalized  with PEG to prevent RES clearance, subsequently enhancing in vivo stability.44 
However, increasing PEG functionalization is at the cost of stimuli-sensitivity and subsequent 
cellular uptake for LS systems.42,44,88 Recent efforts have been exploring routes to better control 
stability and sensitivity LSs using polymeric materials.  
Polymeric nanomaterials are known to have higher in vivo stability and controllable 
guest release than traditional LSs. Various polymer systems have been designed to selectively 
release guest molecules under biologically relevant stimuli such as pH, redox, or temperature.2 
Typical Polymeric materials exploited for intracellular delivery are typical sensitive to pH- or 
redox- stimuli. As mentioned above the acidification throughout endocytosis makes pH-sensitive 
systems promising, and such materials are discussed in more detail within Chapter 1. Similarly, 
increasing reducing environments within cell cytosol along with this being up to 4 times higher 
within tumor tissue2,3,25 has made redox-sensitive nanotherapeutics a popular area of study.3,19,22–
25,29,32 Such systems typically contain disulfide linkages, which are stable under micromolar 
concentrations of GSH, but cleave, to release guest therapeutics, at millimolar GSH 
concentrations. Throughout this work we have decided to exploit a redox-sensitive polymer in 
combination with a pH-sensitive liposome as our dual-stimuli-sensitive LG.  
An array of LG systems have been formulated with varying core, shell, and guest 
components, some of which are responsive to biological stimuli such as temperature65,71 or pH.30 
However, to our knowledge, no reports have used a combination of dual-guest and dual-
responsive characteristic for LGs. Within this work, we have exploited the dual-stimuli-sensitive 
capabilities of our dual-guest loaded LG scaffold. This system is geared towards intracellular 
delivery via a pH and redox redox-sensitive lipid shell and polymer core respectively (Figure 0.2). 
We were able to vary LG formulation to compare sensitivity and uptake of pH-responsive 
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DOPE:CHEMS LGs vs. non-pH-responsive DOPC:CHOL LGs. Throughout both LG formulations, 
rhodamine-labeled lipid (PE-RD), green fluorescent protein (GFP) and/or hydrophobic dye 
probes (DiI and DiD), were used to provide means of characterizing the stimuli-sensitivity and 
intracellular uptake for these systems. Bulk dynamic light scattering (DLS) along with UV-Vis and 
fluorescence spectroscopy was used to confirm the pH and/or redox-sensitivity of LGs. In 
addition to toxicity analysis via cell proliferation assays, the intracellular uptake was monitored 
via confocal light microscopy imaging. Both solution stability, toxicity, and cell uptake analyses 
provided insights to LGs and their potential as a tunable delivery scaffold.  
 
Figure 0.2 Dual-responsive LGs with a pH-sensitive shell and redox-sensitive core   
3.2 Experimental 
3.2.1 Materials 
Di(ethylene glycol) methyl ether methacrylate (DEGM), 2-hydroxy-4′-(2-
hydroxyethoxy)-2-methylpropiophenone (PI), sodium-L-ascorbic acid (AA), sodium hydroxide 
(NaOH), 1,1′-dioctadecyl-3,3,3′,3′-tetramethylindocarbocyanine perchlorate  (DiI), glutathione 
(GSH), and Triton X-100 (TX) were purchased from Sigma Aldrich. 1,1'-dioctadecyl-3,3,3',3'-
tetramethylindodicarbocyanine 4-chlorobenzenesulfonate salt (DiD), NucBlueTM Live 
ReadyProbesTM Reagent (NB; R37605), Live Cell Imaging Solution (A14291DJ), LysoTrackerTM 
Blue DND-22 (LB, L7527), CellMaskTM Deep Red Plasma Membrane Stain (PMDR; C10046), 
redox-sensitive	NG	core
pH-sensitive	lipid	shell
protein	guest
hydrophobic	guest
pH	4-5 redox
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Trypsin-EDTA 0.5 % (15400054), and Dulbecco’s Modified Eagle Medium F-12 (DMEM; 11320033) 
were purchased from ThermoFisher Scientific. Fetal bovine serum (FBS; 66140079) and 100X 
penicillin-streptomycin-glutamine (10378016) were purchased from Fisher Scientific. 
Phospholipids and sterols; 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-
dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-dioleoyl-sn-glycero-3-
phosphoethanolamine-N-(lissamine rhodamine B sulfonyl) ammonium salt (PE-RD), 1,2-
dioleoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] 
ammonium salt (PE-PEG), cholesterol (CHOL) and cholesterol hemisuccinate (CHEMS) were 
purchased from Avanti Polar Lipids Inc. Green fluorescent protein (GFP) was kindly provided by 
our collaborator, Jeanne Hardy (Department of Chemistry, University of Massachusetts – 
Amherst). All listed reagents obtained were used without further purification unless otherwise 
stated.   
3.2.2 Lipogel (LG) Formation 
Similar to methods described in Chapter 2, LS and LG formation, purification, and 
analysis was performed in pH 7.4, 10 mM PBS buffer, and LG concentrations are reported with 
respect to lipid concentration unless otherwise noted. Liposomes (LSs) were composed of a 
60:40:1 molar ratio of DOPE:CHEMS:PE-PEG [DOPE (1.1 mg, 1.5 μmol); CHEMS (0.5 mg, 1.0 
μmol); PE-PEG (70 μg, 25 nmol)]  or DOPC:CHOL:PE-PEG [DOPC (1.2 mg, 1.5 μmol) and CHOL 
(0.4 mg, 1.0 μmol); PE-PEG (70 μg, 25 nmol)]. For rhodamine labeled LGs additional 0.025 % PE-
RD (0.8 μg, 0.6 nmol) was added to the above lipid mixtures. All LSs were made to have a final 
hydrated lipid concentration of 2.5 mM. Lipid and sterol components were mixed in chloroform 
and vortexed before being dried into a film with an argon stream. Films were further dried under 
vacuum overnight before being hydrated with a 5 % (w/v) (50 mg/mL) polymer precursor 
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solution, which contained 95 % monomer and 5 % crosslinker. The crosslinker, N,N’-
bis(methacryloyl)-L-cystine (CDM) was synthesized following a reported method, and 
experimental details can be referred to within Chapter 2.83 Hydration solutions were made by 
sonicating a mixture of DEGM (44 μL, 125 μmol), CDM (5 mg, 6.6 μmol), PI (0.2 mg, 0.9 μmol), 
NaOH (50 μL, 1 M), and PBS (0.5 mL) followed by dilution with additional PBS buffer (0.5 mL). 
For LGs containing protein, GFP (0.5 mL, 100 μM) was added in place of the PBS buffer dilution. 
Precursor and protein solutions were used to hydrate LSs at 2-8 °C for 3 hours; vortexing initially 
and every 1 h to fully disperse the mixtures. Following hydration, LSs were extruded 21 times 
through a polycarbonate membrane (100 nm, 19 mm) using a mini-extruder set (Avanti Polar 
Lipids Inc.). Extruded LSs were then mixed with ascorbic acid (AA) (200 mol % with respect to PI), 
UV irradiated (365 nm, 30 min), and syringe filtered (0.45 μm pore size) to yield the crude LG. 
Hydrophobic cargo was then loaded into the crude LGs by addition of DiI or DiD (0.5 or 10 mol % 
with respect to lipid) in acetone.  After stirring overnight at 2-8 °C, all LGs were syringe filtered 
before dialysis purification in PBS buffer at 2-8 °C for 24-48 h (biotech cellulose ester membrane 
MWCO 300 kDa, Spectrum Labs).  Purified LGs were stored at 2-8 °C until further use.  
Characterization of LS, LG, and bare NG formation was analyzed via DLS of 50 μM 
sample in PBS. To displace the lipid shell, TX (100:1 TX:lipid) was added to LS/LG samples before 
initial size analysis. The bare nanogel (NG) core was obtained after TX lipid displacement and 
dialysis purification (biotech cellulose ester membrane MWCO 100 KDa, Spectrum Labs), which 
is described in more detail within Chapter 2. Hydrophobic guest and protein encapsulation were 
quantified by UV-Vis and fluorescence spectroscopy respectively. Methods for guest 
quantification are described in more detail within Chapter 2. All size analysis was done using 
dynamic light scatting (DLS) on a Malvern Zetasizer Nano ZS. Bulk sample UV-visible (UV-Vis) 
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absorption was monitored on a PerkinElmer Lambda 35 spectrometer, while bulk sample 
fluorescence analysis was performed on a PerkinElmer LS 55 spectrometer. 
3.2.3 Analysis of pH-sensitivity  
LG pH-sensitivity was monitored via Förster resonance energy transfer (FRET). 1-2 mM 
LGs loaded with either 10 mol % DiI (DiI-LG) or 10 mol % DiD (DiD-LG) were separately mixed at 
a 1:1 ratio with buffer to have final pH of 7.7, 6.8, 5.9, or 4.4. Solutions of 66 mM monobasic and 
dibasic potassium phosphate were used for varying pH buffers (Table 0.1). 
Table 0.1 Solution components of buffers and sample for varied pH analysis 
pH % KH2PO4 (67 mM) % Na2HPO4 (67 mM) 
% LS/LG in 
PBS 
7.7 5 45 50 
6.8 30 20 50 
5.9 45 5 50 
4.4 50 - 50 
 
FRET analysis was done by mixing a 1:1 ratio of DiI-LG and DiD-LG solution. Aliquots 
removed from mixtures and diluted to a final concentration of 25-50 μM for UV-Vis and 
fluorescence analysis at individual time points from 0-24 h. Fluorescence emission was 
monitored from 500-800 nm after excitation at 480 nm. Size analysis of DiI-LGs (25-50 μM) mixed 
1:1 with buffer to have final pH of 7.7, 6.8, 5.9, or 4.4 for 24 h before diluting to 25-50 μM with 
PBS or TX-PBS was executed using DLS.  
3.2.4 Analysis of redox-sensitivity  
Redox-sensitivity of samples was determined from mixing a solution of LG/NG (1 mM, 
respective to LG) and GSH (10 mM final concentration) in PBS. After 48h, DLS was monitored of 
solutions prior. TX (100:1 TX:lipid) was then added to displace any lipid or cleaved polymer, and 
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DLS size analysis done again to confirm if LG polymer core or bare NG were cleaved during GSH 
exposure. Redox-sensitivity of lipid shell was monitored via UV-Vis absorption and FRET over 
time following the procedure described within the pH-sensitivity section above. The only 
exception is initial mixing of DiI-LGs or DiD-LGs at a 1:1 ratio was done with 20 mM GSH instead 
of varying pH buffer.  
3.2.5 Cell culture, toxicity, and intracellular uptake 
Cell culture was done at 37 °C with 5 % CO2 in DMEM containing 10 % FBS, 1 % penicillin-
streptomycin-glutamine, and 1 % non-essential amino acids. Digestion of cells was done 
according to ATCC protocol for HeLa and 293T cell lines.   
3.2.5.1 MTT proliferation assay 
Cytotoxicity of LGs was checked with both HeLa and 293T cells lines. Cells were seeded 
in 96 well plates (16,000-32,000 cells/cm2) and incubated for 24 h before replacing seeding media 
with sample/control solutions. LG samples were diluted in culture media to achieve desired 
concentrations of 13-200 μM. Media with PBS (respective to % PBS added in sample dilutions) 
and 0.5 % trypsin were used for positive and negative controls respectively. After incubating cells 
with samples for 24 h, MTT (10 μL, 5 mg/mL in DMEM) was added to each well. After an 
additional 3 h incubation, culture plates were spun down (3,700 rpm, 10 min) and supernatant 
removed. DMSO (50-100 μL) was added to each well and absorbance checked at 540 nm and 630 
nm on a Spectramax M5 Spectrophotometer. 
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3.2.5.2 Cell uptake via confocal microscopy analysis 
Intracellular uptake performed with HeLa cells seeded at 30-50% confluency (~10,400 
cells/cm2) in a 4-chamber 35 mm glass bottom dish. After incubating cells for 12-16 h, culture 
medium was removed and cells were washed once with PBS before adding new culture media 
containing 100 μM NF-LG, GFP-LG, RD-LG, DiD-LG (0.5 % DiD loading), GFP-RD-LG, or DiD-
GFP-RD-LG (0.5 % DiD loading). Cells were incubated with LG for 4 h and nuclear, plasma 
membrane and/or lysosomal labeling was done during the final 5-120 min of sample incubation 
using NucBlueTM (NB, 80 μL per mL media, 30-60 min), CellMaskTM Deep Red Plasma Membrane 
Stain (PMDR, 1X, 5-10 min), and/or LysoTrackerTM Blue DND-22 (LB, 1.0 μM/mL media, 90-120 
min) respectively. After sample and stain incubation, media was removed and cells were washed 
2-4 times with PBS. Live cell imaging buffer were added to cells and cell uptake analysis was done 
using a Nikon Yokogawa spinning disk confocal microscope equipped with 40x or 100x oil 
objectives, and an Andor EMCCD camera for image collection. Distribution of sample throughout 
individual cells was monitored with z-stack imaging at 100x, while snapshot images at 40x were 
used to see distribution of uptake among multiple cells. When noted, imaging was also done 
using a Nikon A1 resonant scanning confocal microscope equipped with a 60x oil objective and 
Andor Xyla camera. Uptake of RD-, GFP-, and/or DiD- (0.5 % loading) was monitored using 488, 
561, and 640 nm wavelength lasers respectively. NB, LB, and PMDR were detected with either 
405 or 640 nm wavelength lasers. To account for signal bleed between fluorescent channels, all 
LGs were monitored with 405, 488, 561, and 640 nm wavelength lasers and images compensated 
accordingly. 
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3.3 Results and discussion  
Methods established within Chapter 2 were utilized for LG formation. In brief, LGs were 
composed of either DOPE:CHEMS or DOPC:CHOL lipid mixtures, containing 1 % PE-PEG, and 
PE-RD in LGs with rhodamine-label for tracking cellular uptake of LGs (Figure 0.3).88 The mixed 
lipids were dried into thin films and hydrated with an aqueous solution containing 95 % monomer 
(DEGM), 5 % crosslinker (CDM). Protein was loaded by adding GFP to the DEGM/CDM mixture 
prior to lipid hydration (Figure 0.3a). After hydrating lipids with the polymer precursor and 
protein mixtures, samples were extruded to have monodisperse sizing of LS templates before 
UV irradiation to polymerize the nanogel core yielding LGs (Figure 0.2b). Polymerization outside 
of LS templates was inhibited by adding a photo inhibitor, AA, just before exposing to UV 
irradiation.59,67 After LG formation, hydrophobic guest molecules, DiI or DiD were loaded into 
bulk LGs (Figure 0.3). Both DiI and DiD are insoluble in aqueous solutions, but both were 
solubilized within LG solutions. This validates hydrophobic guest sequestration within the lipid 
bilayer shell. After formation and guest loading, LGs were purified via dialysis to remove any un-
encapsulated small molecules or proteins.  
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Figure 0.3 LG composition of (a) polymer precursors, (b) nanogel core, and (c) lipid shell, along 
with (d) DLS analysis of LS, LG, and NG formation 
Verification of LG core crosslinking was done via size comparing the TX treated LSs and 
LGs. TX displaced LS and LG lipid shell into TX-lipid (TX-L) mixed micelles (~10 nm). After UV 
irradiation of LSs into LGs, the NG core size was detectible after TX-L displacement, confirming 
LG formation from the LS template (Figure 0.3d). After confirming nanogel (NG) core 
crosslinking, the TX-L mixed micelles were removed via dialysis to obtain the bare NG. 
Fluorescence and DLS analysis before and after NG purification confirmed full removal of lipid 
shell, which is described in more detail within Chapter 2. Similar size distribution (~150-200 nm) 
of LS, LG, and bare NG samples verified the LS indeed acted as a template for NG core 
crosslinking (Figure 0.3d).  
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3.3.1 pH-sensitivity of DOPC:CHOL LG vs. DOPE:CHEMS LG 
Sensitivity to pH of the lipid shell was monitored by tracking hydrophobic guest 
exchange of DOPE:CHEMS or DOPC:CHOL LGs within pH 4.4-7.7 solutions. Unlike DOPE and 
CHEMS LSs, their phosphatidylcholine and cholesterol derivatives, 1,2-dioleoyl-sn-glycero-3-
phosphocholine (DOPC) and cholesterol (CHOL), have significantly lower cytoplasmic delivery.4,9 
DOPC:CHOL systems require additional lipid and/or guest components to promote pH 
sensitivity66,100 and/or intracellular uptake.103,104 Due to the similarity in lipid and sterol structure, 
but stark differences in sensitivities, we have used a DOPC:CHOL scaffold as a control non-
stimuli-sensitive LG system throughout this work.  
 Initially, LGs were separately loaded with either DiI (fluorescent donor) or DiD 
(fluorescent acceptor) and referred to as DiI-LGs or DiD-LGs, respectively.  When DiI and DiD 
come in close proximity, increasing FRET occurs over time, implying exchange or leakage of 
DiI/DiD guests between LGs. Alternatively, if FRET increase does not occur over time, we can 
confidently report DiI/DiD guests are stably encapsulated within the lipid shell. DiI-LG and DiD-
LG solutions were mixed within pH 4.4-7.7 solutions and the FRET ratio was monitored over time. 
Analysis of this was done by plotting FRET ratio Ia/(Id + Ia) vs. time, where Ia and Id are the 
maximum emission intensity of the acceptor (DiD) and the donor (DiI) at 681 and 582 nm 
respectively. The non-pH-sensitive DOPC:CHOL LGs were used as a control LG, which had 
minimal FRET observed, regardless of pH change (Figure 0.4a). Additionally, the constant FRET 
ratio over time further confirmed DOPC:CHOL LGs were stable with minimal guest leakage 
within pH 4.4-7.7 solutions (Figure 0.4b).  
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Figure 0.4 DOPC:CHOL LG (a) fluorescence and (b) FRET ratio over time under varying pH  
Alternatively, DOPE:CHEMS LGs had increasing FRET as sample pH was decreased from 
pH 7.7-4.4 (Figure 0.5a). The increasing FRET ratio over time further verified DOPE:CHEMS LGs 
were pH-sensitive with higher guest leakage from pH 4.4-5.9 compared to pH 6.8-7.7 (Figure 
0.5b). Despite the increasing or stagnant FRET ratio, UV-Vis absorption at each time point 
confirmed hydrophobic guest concentration was maintained over time with both DOPE:CHEMS 
LGs and DOPC:CHOL LGs. Full fluorescence and UV-Vis absorption spectra for individual time 
points of DOPC:CHOL and DOPE:CHEMS LG FRET analyses can be referred to within Appendix 
B.  
To verify maintained size and core integrity for DOPE:CHEMS LGs, DLS of LGs before 
and after TX lipid shell displacement was executed. Results verified that the LG size was 
maintained at pH 7.7-5.9 but appeared to swell at pH 4.4 ( 
Figure 0.6a). Despite such swelling, the NG core integrity remained intact, as observed 
by the presence of crosslinked NG (~ 150-200 nm) after TX lipid displacement ( 
Figure 0.6b). Overall FRET results verified DOPE:CHEMS LGs were indeed pH-sensitive. 
In addition, as expected the redox-sensitive crosslinked NG core was maintained despite acidic 
LG destabilization.  
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Figure 0.5 DOPE:CHEMS LG (a) fluorescence and (b) FRET ratio over time under varying pH  
 
Figure 0.6 DOPE:CHEMS LG size at pH 7.7-4.4 (a) before and (b)  after TX lipid displacement  
3.3.2 Redox sensitivity of LG vs. NG 
Redox-sensitivity of the NG core vs LG was also characterized through DLS and FRET 
analysis. DOPE:CHEMS LGs or bare NGs (derived from DOPE:CHEMS LGs) were analyzed within 
normal (PBS) or reducing (GSH) environments. A concentration of 10 mM reduced GSH was used 
to represent known intracellular redox concentrations.3,25 DiI-LG and DiD-LG mixtures were 
monitored via FRET analysis to determine LG lipid shell stability under normal (nLG) or reducing 
(GSH-LG) environments. Normalized fluorescence revealed minimal FRET with nLGs FRET, 
although significant FRET was observed with GSH-LGs (Figure 0.7a). The FRET ratio over 24 h 
remained low for nLGs, but significantly increased with GSH-LGs, to further confirm that GSH 
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was destabilizing the lipid shell (Figure 0.7b). Full fluorescence and UV-Vis absorption spectra for 
FRET analyses before and after redox can be referred to within Appendix B. 
 
Figure 0.7 LG in PBS (nLG) vs. redox (GSH-LG) (a) fluorescence and (b) FRET ratio over time  
Despite GSH lipid destabilization, minimal size change was observed between the nLG 
and GSH-LG samples (Figure 0.8a). After TX addition, the polymer core (~150-200 nm) remained 
intact in both nLG and GSH-LGs (Figure 0.8b), which confirmed the lipid shell acted as a 
protective barrier to avoid redox core cleavage.  
To confirm the NG core was redox-sensitive, size analysis was also done on the bare NG 
under the same conditions, normal (nNG) or reducing (GSH-NG). Interestingly, minimal 
difference in size was observed between nNG and GSH-NGs (Figure 0.9a). Since both lipids and 
un-crosslinked polymer aggregates are readily displaced by TX, addition of TX was done as 
means to analyze if the NG core was indeed cleaved by GSH. Similarly, nNG size (~150-200 nm) 
was also maintained after TX addition, but after TX addition to the GSH-NG, complete 
displacement of NG size was observed (Figure 0.9b). This phenomenon confirmed the bare NG 
was indeed sensitive to reducing conditions. 
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Figure 0.8 nLG vs. GSH-LG size (a) before and (b) after TX lipid displacement  
 
Figure 0.9 NG in PBS (nNG) vs. redox (GSH-NG) size (a) before and (b) after TX lipid 
displacement  
3.3.3 Cytotoxicity of LGs 
Beyond demonstration and analysis of bulk LG pH- and redox-sensitivities, we executed 
cytotoxicity and intracellular uptake analyses. Cytotoxicity of LGs was checked using the MTT 
cell proliferation assay. Toxicity was monitored for LGs in both HeLa and 293T cell lines to 
confirm viability regardless of whether cell populations are carcinomic or healthy. For all analysis, 
positive and negative controls were done by treating cells with either culture medium (with <10 
% PBS) or 0.5 % trypsin respectively. To confirm LGs were inherently non-toxic, initial viability 
was monitored for empty, non-fluorescent DOPE:CHEMS LGs (NF-LG). Both HeLa and 293T cells 
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demonstrated >80 % viability after incubation with NF-LGs with concentrations ranging from 13-
200 µM (Figure 0.10a). Additional LGs labeled with rhodamine (RD-LG) and/or encapsulated with 
GFP (GFP-RD-LG, GFP-LG) also demonstrated >80 % viability when incubated at the highest 
concentration, 200 µM, with both HeLa and 293T cell lines (Figure 0.10b). Compiled toxicity 
analysis verified formulated LG variants were non-toxic and concentrations up to 200 µM could 
be used for intracellular uptake analysis.   
 
Figure 0.10 HeLa and 293T toxicity of (a) NF-LG (13-200 µM) and (b) GFP-LG, GFP-RD-LG, and 
RD-LG (200 µM).  
3.3.4 LG intracellular uptake 
Initial cell uptake was done with GFP-RD-LGs that contained either DOPC:CHOL or 
DOPE:CHEMS lipid shells. HeLa cells were incubated with GFP-RD-LGs for 4 h before imaging 
via scanning confocal microscopy As anticipated, GFP-RD-LGs with a DOPC:CHOL lipid shell did 
not appear to have significant cell uptake of RD or GFP even after 8 h. of incubation. 
Alternatively, the GFP-RD-LG coated with DOPE:CHEMS lipids had cell uptake of both RD and 
GFP (Figure 0.11). The difference in cell uptake of DOPC:CHOL vs. DOPE:CHEMS coincides with 
their difference in pH-sensitivity, which further verified that LG pH-sensitivity played a significant 
role in cell uptake phenomenon.   
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Figure 0.11 HeLa cell uptake of (a) DOPC:CHOL vs. (b) DOPE:CHEMS LGs. Z-stack projections 
overlay of NB, GFP, RD, and bright field (top only)  
To ensure intracellular fluorescence signal did not occur inherently from the LG itself or 
from free GFP, cell uptake analysis was also executed with DOPE:CHEMS NF-LGs or free GFP 
controls. HeLa cells were incubated with NF-LG or free GFP for 4 h before confocal microscopy 
imaging. Individual cell images are maximum intensity projections of a z-stack image overlays of 
all channels to ensure no signal throughout the cell. Within both wide array and z-stack 
projections, no cell uptake was observed for either control (Figure 0.12). 
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Figure 0.12 HeLa cell uptake of (top) free GFP vs (bottom) DOPE:CHEMS NF-LG 
After confirming DOPE:CHEMS LGs were readily taken up into cells, we characterized 
their ability to deliver separate guest molecules within the cell. Cell uptake was performed on 
individually labeled/encapsulated LGs (GFP-LG, RD-LG, DiD-LG) in addition to dual-loaded 
labeled LGs (DiD-GFP-RD-LG). Distribution of lipid (RD), protein (GFP), or hydrophobic guest 
(DiD) was monitored throughout individual cells and among multiple cells was for each sample. 
GFP-, RD-, and DiD-LGs were all taken up by HeLa cells. Maximum intensity projections of single 
cell z-stacks for individual 405 (blue), 488 (green), 561 (red), and 640 (magenta) nm channels 
were overlayed into composite images to observe distribution of GFP (green), RD (red) and/or 
DiD (magenta) respectively (Figure 0.13).  
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Figure 0.13 HeLa cell uptake of (a) GFP-, (b) RD-, (c) DiD-, and (d) DiD-GFP-RD- LGs. Z-stack 
projections overlay of NB, GFP, RD, DiD and bright field (top only)  
Lower magnification images were also taken to show a larger cell population, verifying 
that cell uptake is not segregated to specific cells. Additionally, these images confirm there is 
minimal signal bleed through of fluorophores between different laser channels. (Figure 0.14). To 
better determine where the LG is traveling within the cell and more importantly, if protein is 
released after intracellular uptake, further analysis was executed to track LG uptake across 
different organelles using specific cell labeling of the plasma membrane and/or lysosome.  
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Figure 0.14 HeLa cell uptake of (a) GFP-, (b) RD-, (c) DiD-, and (d) DiD-GFP-RD- LGs under 
individual (488, 561, and 640 nm) lasers and the overlay composites   
3.3.5 Intracellular distribution of LGs  
The plasma membrane and lysosome of Hela cells were labeled with PMDR and LB 
respectively. Due to fluorescence overlap with PMDR, LGs with DiD were not monitored with 
PMDR labeled cells. Since cyanine dyes such as DiD, are known to readily diffuse within cell 
membranes,105 we focused our attention on monitoring the distribution of lipid and protein cell 
uptake.  Distribution of RD and GFP was monitored with respect to PMDR and/or LB after 
incubation of cells with GFP-RD-LGs. Uptake analysis of GFP-RD-LGs rather than individual GFP-
LG or RD-LGs also provided means to monitor separation of RD and GFP within the cell, as 
evidence to intracellular LG guest release. Distribution of GFP and RD throughout the cell was 
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monitored using z-stack imaging, and composite images of a single z-stack image within the 
middle of each cell are provided to reiterate the dispersion of GFP and RD within and beyond the 
PMDR and/or LB. For better contrast and easier comparison, the PMDR and LB signals were 
converted to blue and cyan respectively, while GFP and RD uptake are shown as green and red 
respectively.  
When monitoring GFP and RD uptake with respect to each other, we observed that 
minimal GFP existed independently, but rather primarily colocalized with RD signal. This is clear 
with the lack of green GFP signal within the RD and GFP image overlay. Interestingly, we 
observed that majority of the GFP (regardless of colocalization with RD) was colocalized with 
PMDR (Figure 0.15b), but minimal to no GFP overlapped with LB (Figure 0.15c). Additional RD 
(beyond colocalized GFP-RD signal) was found to be localized with both the PMDR and LB. Such 
results were evidence that LGs were indeed undergoing endocytosis, despite the lack of GFP-LB 
colocalization. Overlaying images into a composite, revealed that RD exists outside of either 
PMDR or LB (Figure 0.15d). This observation eluded to LGs escaping endocytotic vesicles. 
However, due to the pH sensitivity of GFP106, causing fluorescent activity loss, it is unclear if GFP 
was also released within the cell cytosol. Further verification of the cell uptake phenomenon can 
be observed from images of GFP, RD, and/or DiD distributions with respect to PMDR or LB in the 
top, middle, and bottom of cell z-stacks (Appendix B).  
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Figure 0.15 HeLa cell uptake of GFP-RD-LG via z-projection overlays of (top) GFP, (middle) RD, 
or (bottom) GFP and RD signal (a) alone or with (b) PMDR, (c) LB, or (d) PMDR and LB 
3.4 Conclusion 
Within Chapter 3 we characterized the stimuli-sensitivity, cytotoxicity, and intracellular 
uptake for a dual-responsive LG composed of a pH-responsive lipid shell and redox sensitive NG 
core. Tunable sensitivity and preferential cell uptake was displayed by comparison of pH-
sensitive (DOPE:CHEMS) LGs vs. non-pH-responsive (DOPC:CHOL) LGs. DOPC:CHOL LGs 
demonstrated stability within solutions of pH 4.4-7.7, while DOPE:CHEMS LGs were readily 
destabilized within solutions of pH 4.4-5.9. Additionally, DLS results confirmed the NG core was 
not disassembled despite lipid destabilization of LGs from decreased pH. Redox-sensitivity of the 
NG core was confirmed by GSH cleavage of NGs, which subsequently resulted in disassembly 
with TX. Lipid destabilization was observed after exposing LGs to GSH, although the NG core 
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remained intact regardless of GSH exposure and TX addition. Such phenomenon confirmed the 
lipid shell protected the NG core from redox cleavage. Toxicity analysis demonstrated that LGs 
were inherently non-toxic up to 200 µM in both HeLa and 293T cell lines. Intracellular uptake of 
GFP, RD, and DiD was done with HeLa cells and analyzed via confocal microscopy to confirm 
preferential cell uptake of pH-sensitive DOPE:CHEMS LGs vs. non-pH-sensitive DOPC:CHOL 
LGs. Individual uptake RD, GFP, and DiD was observed in HeLa cells. Uptake analysis with PMDR 
and LB confirmed LGs were undergoing endocytosis. LG was observed to escape endocytotic 
vesicles, although further systems will need to be characterized to confirm protein is released 
within the cell cytosol. Overall this work confirmed formulated LGs have a pH sensitive lipid shell 
and redox sensitive NG core, and are good candidates for intracellular delivery via parenteral 
administration. Unfortunately, patient compliance and cost greatly inhibit parenteral 
therapeutics, and designing nanotherapeutics for different administration routes (e.g. 
transdermal, oral, or pulmonary), would have much greater impact. This led us to extend our 
material scaffolds towards delivering materials via oral administration, which is discussed in 
more detail within Chapter 4.  
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CHAPTER 4 
 
DESIGNING LIPID AND POLYMER SCAFFOLDS FOR ORAL NANOTHERAPEUTICSd 
4.1 Introduction 
Current methods of drug delivery include intravenous, oral, and transdermal routes. 
Typically, sensitive peptide or protein (PP) molecules are delivered via parenteral routes (e.g. 
intravenous, subcutaneous), although newer technologies involving transdermal107–109 and oral 
delivery110–113 of PPs are being widely studied. In particular, oral delivery is very desirable due to 
being minimally invasive with higher patient compliance relative to parenteral administration. 
Majority of orally administered therapeutics are successful at delivering small molecules but lack 
the ability to deliver macromolecules or nanoparticles. This is not only due to the larger size and 
solubility of materials, but also their sensitivity toward degradation.112 Additionally, due to the 
harsh conditions present within the digestive system, delivery of enzyme and/or pH sensitive PPs 
is especially difficult.110 Understanding the barriers to oral delivery and materials which can 
overcome them is crucial to designing oral nanotherapeutics. As relayed through previous 
chapters the tunability of lipogels (LGs) holds potential use delivering therapeutics via different 
administration routes, and we have geared specific formulations towards oral administration. 
Throughout this chapter the oral barriers, nanomaterial design, and preliminary stability analysis 
of liposome (LS) and amphiphilic polymer nanogel (ANG) scaffolds will be highlighted. 
                                                                    
d Content of this chapter was adapted from published manuscript: 
2 Homyak, C.; Anson, F.; Thayumanavan, S. In Comprehensive Supramolecular Chemistry II;         
Atwood, J. L., Ed.; Elsevier, 2017; Vol. 5, pp. 227–254. 
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4.1.1 Barriers to oral delivery  
Before reaching circulation molecules must cross a series of chemical, enzymatic, and/or 
physical barriers within each portion of the GI tract.110,111 Throughout the gastrointestinal (GI) 
tract, there are four major sections: (i) oral cavity, (ii) stomach, (iii) small intestine, and (iv) large 
intestine (colon). Each GI section has specific functions for aiding in digestion and nutrient 
absorption, and understanding the barriers to each is crucial to designing nanotherapeutics for 
oral administration.  
4.1.1.1 Oral cavity 
Throughout the oral cavity, there are chemical and enzymatic barriers to consider, 
although in much less quantity than within the stomach and small intestine. Saliva has a pH ~5-
7114 and is composed of water, mineral salts (Na+, K+, Cl-, and HCO3-),90 mucus, proteins, and 
amylases.90 To maintain moisture and prevent starchy mucus accumulation, watery saliva with 
amylase is constantly being secreted within the mouth at a rate of 0.5-0.7 mL/min.90 Enzymes 
such as ptyalin help with polysaccharide degradation, and also remain active until reaching the 
acidic pH of the stomach.90 Due to the short residence time within the oral cavity (~5-60 s),114 it 
is not typical for therapeutics to be absorbed within the oral mucosa.90 Prolonging the residence 
time of materials via addition of hydrophobicity can enhance oral absorption, but such materials 
must also be soluble within the saliva to prevent from being swallowed intact.90  
4.1.1.2 Stomach 
Typically, molecules will enter the stomach from the oral cavity and reside within the 
gastric compartment anywhere from 30 minutes to a few hours.114 PPs and lipids undergo 
enzymatic degradation from increased concentration of pepsin and gastric lipase within the 
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stomach. Both of these enzymes are active at the acidic pH of the stomach fluid.115 The stomach’s 
inherently acidic lumen (pH 1-3)114 is the harshest chemical barrier throughout the GI tract. Mucus 
coated (300 μm thick)37 epithelial cells are in constant pH gradient flux  to maintain  lumen acidity. 
This harsh combination of physical and chemical barriers, hinder materials from easily 
permeating the stomach epithelium to reach blood circulation. Furthermore, absorption of 
nanomaterials often requires opening of epithelial tight junctions letting larger materials and 
subsequent luminal content through the epithelium, which is not feasible due to toxic leaching 
of stomach fluid into the body.  
4.1.1.3 Small intestine  
The small intestine is made up of three sections; the duodenum, jejunum, and ileum in 
order from the stomach to colon respectively.110 When transferred from the stomach to the small 
intestine, gastric juice will deposit into the duodenum. In combination with gastric juice, bile 
salts, bilirubin, cholesterol, and phospholipids are added from the gallbladder and liver to 
neutralize acidic gastric fluid, causing changes in ionic strength to reach the relative pH in the 
small intestine of 6-7.5.114 Bile salts are also necessary for emulsification and absorption of fat 
content within food via submicron mixed micelles.90 Similarly, depending on fat content entering 
the small intestine, a cocktail of pancreatic enzymes are released within the duodenum.90 
Enzymes are fully activated within in the jejunum making this the highest enzymatic barriers for 
oral delivery. Proteases, lipases, and amylases are commonly excreted within the small intestine 
and are responsible for the majority of food digestion within the GI lumen.90 Final nutrient 
absorption occurs within the ileum before components are passed onto the colon, with typical 
residence time in the small intestine of 1-2 hours.114 One of the largest challenges to oral delivery 
is the enzymatic degradation of biomolecules such as PPs vs. small molecule therapeutics. This 
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runs in tandem with the minimal absorption of materials larger than 500 kDa. Furthermore, small 
molecules can be synthetically designed to avoid enzymatic degradation and have better 
diffusion through mucus and epithelial cells in comparison to larger nanomaterials or biologics. 
Current research has focused on expanding upon strategies to enhance oral stability and 
absorption of both nanomaterials and biologics such as PPs.53,113,116 Despite enhancing the 
stability of therapeutics within the small intestinal lumen, an equally challenging setback is 
crossing the mucus lined GI epithelium.  
4.1.1.4 Mucus & epithelial barrier 
Mucus coated epithelial cells act as a physical barrier to oral absorption, which is easily 
the largest barrier for nanotherapeutics to cross. There is a thick layer of firm and loose mucus 
coating the intestinal epithelium.113 Thickness of mucus layers varies throughout the GI tract but 
is thinnest within the jejunum, which is an advantageous target for therapeutic absorption.113 The 
mucus layer is one of the most difficult physical barriers to overcome in oral delivery due to its 
complex mesh structure that is constantly being shed off and regenerated to eliminate absorbed 
contaminants.113  
Mucus is a highly glycosolated flexible hydrogel network composed of lipids, proteins, 
carbohydrates, salts, antibodies, and cellular debris.113 The protein composition throughout 
mucus is mainly composed of mucins. Within loosely adherent mucus closest to the GI lumen, 
secreted mucin monomers are crosslinked together via reversible disulfide bonds, forming a 
shear viscoelastic gel.113 Firmly adherent mucus composed of cell-bound mucins and glycocalyx, 
lies between the loosely adherent mucus and GI epithelium.113 Glycosylation on mucin proteins 
prevents mucus degradation via intestinal proteases.113 Once absorbed through the mucus layer, 
molecules reach the inner most layer of the GI tract epithelium, the mucosa. To cross mucosa 
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cells, molecules need to follow transcellular (through the cell) or paracellular (around the cell) 
pathways. Molecules can also permeate through GI epithelial cells via receptor-mediated 
transcytosis within epithelial or M-cells of Peyer’s patches, although these methods require 
specific active targeting functionality.112 Despite being scattered around the intestinal 
epithelium, M-cells are advantageous to target due to their increased transcytotic capacity and 
minimal mucus and glycolax cell surface coating.38 (Figure 0.1) 
 
Figure 0.1 Crossing GI mucus and epithelial barrier2  
4.1.1.5 Colon 
Any residual material that remains within the GI tract goes into the colon. Despite the 
neutral pH (~5-7), significantly higher concentrations of bacteria reside in the colon, unlike other 
GI environments. Concentrations of bacteria within the human colon are around 1011 colony-
forming units/mL. Despite colon bacteria variants forming proteases, the proteolytic activity in 
the colon remains 20-60 times less than within the small intestine.55 When targeting the colon, it 
is important to note the residence time of materials within the colon is almost 10 times longer 
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than other areas of the GI tract. Due to the low proteolytic activity and longer residence time, 
recent efforts have been expanding on delivering PPs to the colon for absorption into the blood 
stream.  
4.1.2 Materials for oral nanotherapeutics 
Knowledge of the GI barriers has shed light on requirements for successful oral delivery 
of larger macromolecules and nanotherapeutics. Protection and delivery of biomolecules such as 
PPs against oral barriers has been an existing challenge throughout therapeutics. Majority of the 
ongoing clinical trials in nanomedicine are geared towards oral PP delivery, many of which utilize 
small molecule or inorganic colloids combining enzyme inhibitors, permeation enhancers, and/or 
mucoadhesive materials.55,117 Since our work focuses on LS and polymer materials, we have 
outlined key designs for overcoming oral barriers using these two materials.  
4.1.2.1 LS materials for overcoming oral barriers   
An array of lipid based materials have been used for pre-clinical and clinical oral delivery, 
such as solid lipid nanoparticles (SLNs),118 polymerizable lipid nanoparticles,55  or liposomes.119 
As described in Chapter 1-3, LSs hold great advantage due to their dual-loading capacity, 
aqueous solubility, and self-assembling nature. Additionally, LSs are known to have improved GI 
membrane permeability.119 However, a large caveat to LSs is their instability within the harsh 
chemical and enzymatic conditions throughout the GI tract. LS systems can be easily modified 
to enhance their stability within GI fluids.  
To enhance stability within the GI lumen and absorption through the GI mucosa, LSs are 
commonly surface functionalized with polymer materials. Functionalizing LSs with 
poly(ethylene glycol) (PEG) helps prevent enzyme degradation within the GI lumen, in addition 
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to prolonging guest release over time within both GI tract and/or blood circulation. Surface 
functionalizing LSs with biopolymers, such as chitosan or pectin can increase therapeutic 
bioavailability due to promoting mucoadhesion with prolonged LS residence within the GI 
mucosa.38,115,120   
Phosphatidylcholine (PC) lipids are commonly utilized within many lipid-based oral 
therapeutics. PC lipids are naturally occurring from egg or soybean but also synthetically derived 
from lecithin.39  Beyond being readily available, many benefits have been discovered from using 
PC within oral delivery formulations.  For example, PCs are known to increase therapeutic 
stability and absorption within the GI tract to enhance bioavailability of various therapeutics. PCs 
can also promote lymphatic absorption of guest molecules into blood circulation, in return 
decreasing the first-pass effect observed with more common capillary absorption of 
therapeutics.39 Additionally, PCs have been commonly used as an additive to non-steroidal anti-
inflammatory drugs (NSAIDs), to decrease formation of gastric ulcers or haemorrages. PCs 
promote prostaglandin synthesis, which are important for protecting gastric cells from 
irritation.39,116   
In regard to oral PP delivery via nanocarriers, there are an array of LS scaffolds being used 
clinically. One example within Phase II clinical trials is HDV-I (Diasome Pharma), which is a liver-
targeted liposome for insulin delivery.55 Orasome (Endorex) is an example of a polymerizable LS 
system being used for the oral delivery of polypeptides, insulin, or human growth factors.119 
Based on previous success of LSs being clinically available via intravenous,18 or transdermal37 
administration routes, it is likely such systems with succeed  via oral administration as well.
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4.1.2.2 Polymer materials for overcoming oral barriers   
Therapeutics are commonly put within enteric coatings or capsules to withstand the 
stomach’s harsh pH.116,117,121 Enteric materials are composed of ionizable hydrogels, that are 
unaffected by acidic pH and remain insoluble within the stomach.121 As pH increases within the 
small intestine, enteric polymers ionize, swell, and dissolve to release therapeutics.121 Based on 
the coating thickness and dissolution pH (dpH) of polymers, enteric hydrogels can be tunable to 
release under specific biological areas.121 Commonly utilized synthetic and natural enteric 
polymers are shellac (dpH 7.0), poly(methacrylic acid-co-methyl methacrylate (PMA-co-PMMA) 
(dpH 5.5-7.0), poly(vinyl acetate phthalate) (PVAP) (dpH 5.0), cellulose acetate phthalate (CAP) 
(dpH 6.2), cellulose acetate trimellitate (CAT) (dpH 5.0), and hydroxypropyl methylcellulose 
phthalate (HMP) (dpH 4.5-5.5) ( 
Figure 0.2).121 Delivery of nanomaterials and larger macromolecules commonly utilizes 
enteric polymer coatings or capsules for enhancing stability throughout the GI tract,117 and due 
to the long standing knowledge on enteric coatings, their formulations will not be further 
discussed.111,117,121–125  
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Figure 0.2 Polymers used for enteric coatings2 
Adding nanoparticle surface ligands such as mannose, mannosamine, or transferrin can 
target M-cell penetration. Similarly, cell-penetrating peptides containing arginine-glycine-
aspartate (RGD) or cysteine (Cys) residues enhance M-cell penetration.38 Addition of Cys on 
particle surfaces can also enhance mucoadhesion and internalization via di-sulfide formation 
between Cys and glycosolated proteins on the mucosal surface.38 Mucoadhesive and 
mucopenetrating materials are a common way to overcome the mucus barrier within the 
intestine. Many of such materials also act as cellular permeation enhancers for crossing GI 
epithelial cells to reach blood circulation.   
Typical orally administrated polymer nanomedicines are derived from combinations of 
amphiphilic polymers such as poly(lactic acid) (PLA), poly(lactide-co-glycolide)acid (PLGA), PEG, 
and/or poly(ε-caprolactone) (PCL).38 Various polymer combinations have been shown to enhance 
GI absorption, and in many cases also incorporate natural polymer derivatives such as albumin 
(AL), dextran (DX), chitosan (CS), trimethyl-chitosan, triethyl-chitosan, polyarginine, and 
poly(glutamic acid).38,54 Studies have shown that surface functionality can greatly affect the 
ability and route in which nanoparticles cross the GI mucosa. Addition of hydrophilic PEG or DX 
coating on nanoparticles can enhance mucopenetration, while positively charged CS derivatives 
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or hydrophobic polymers (e.g. PLA, PLGA, PCL)37 provide stronger mucoadhesive character.38 
Derivatives of CS also have the ability to open tight junctions, allowing for paracellular 
nanoparticle absorption.38 This is thought to be from electrostatic interactions between the 
mucosal membrane and positive charged CS.38 Interestingly, positively charged CS or 
polyarginine materials also have enhanced transcellular permeation that occurs in tandem with 
paracellular permeation.38 Negatively charged polymers such as carbopol or polyacrylic acid 
derivatives also have the ability to promote opening of tight junctions, but rather through 
removal of calcium throughout the extracellular matrix.116 Another advantage to anionic 
polymers is their ability to inhibit enzymes throughout the GI lumen. Addition of enzyme 
inhibitors is a popular method to minimize enzymatic degradation and stabilize carriers within 
the GI lumen. Currently, many approaches to deliver nanotherapeutics orally utilize co-
formulation of therapeutics with mucoadhesive, mucopenetrating, cell permeating, and/or 
enzyme inhibiting components.53,113,116 If therapeutics are not absorbed within the small 
intestine, they will continue digesting in the colon. Coating nanomaterials with non-enzyme 
degradable polymers (i.e. polysaccharide derivatives) eliminates enzyme degradation within the 
small intestine. Furthermore, such materials are easily cleavable via bacteria within the colon, 
allowing for colon specific delivery and release. Despite this, ongoing clinical formulations for 
oral nanotherapeutics do not typically target the colon.  
Beyond these few examples, there is an array of polymer nanomaterials that are under 
investigation for oral absorption, with emphasis on PP delivery.54,55 With the current push for 
biomolecule therapeutics and nanomedicine, results of current orally administered pre-clinical 
and clinical nanomaterials will have great impact on the optimal stability and absorption of orally 
administered nanomedicines. 
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4.1.3 Tuning LG and NG scaffolds for oral delivery 
Due to the vast complexity of testing material’s stability, permeability, and most 
importantly, their ability to delivery cargo orally it is necessary to break down GI conditions along 
with material design to better understand the interactions of individual GI and/or scaffold 
components. With that, this work is primarily focused on establishing methods to monitor the 
stability of nanomaterials within simulated GI fluids. Formulations which display good stability 
within GI fluids, will then be continued on to monitor epithelial permeability, although such 
analysis is beyond the scope of this dissertation work. Additionally, we focused on looking at 
initial oral stability of LSs, which would be converted into LGs at a later time. Beyond LS and LG 
scaffolds, additional analysis was also done with our group’s poly(ethylene glycol) (PEG) : 
pyridyldisulfide (PDS) amphiphilic random copolymer scaffold. Due to self-assembling 
characteristics, tunable scaffold components, and ease of hydrophobic guest encapsulation with 
these amphiphilic nanogels (ANGs), we used this as a system to monitor model guest stability in 
addition to monitoring ANG stability as a potential oral delivery scaffold.   
Within this work we performed initial characterization of stability for LS and ANG 
systems when exposed to simulated GI fluids. The LS system was formed from a 
DOPC:CHOL:PE-PEG mixture, which was loaded with a hydrophilic self-quenching dye, calcein 
(CC). Both the loading of CC within LSs and stability analysis of LSs was done within simulated 
gastric fluid (SGF). Due to the low stability of CC in GI fluids, further analysis of stability for 
different dyes (FL, RD, DiO, DiI, DiD) was done to determine the most stable model guest to use 
in further systems. The previously established PEG:PDS ANG scaffold73,74 was used to 
encapsulate and solubilize the different dyes for testing stability within simulated saliva (SSF), 
gastric (SGF), and intestinal fluids (SIF). Due to the flexibility of the ANG scaffold, we extended 
this work to monitor initial stability these materials within SSF, SGF, and SIF as well. Analysis of 
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the ANG stability with varying amounts of PEGylation was done as preliminary analysis to show 
the effect surface functionality has on ANG GI stability.  
4.2 Experimental  
4.2.1 Materials 
Calcein (CC), Fluorescein (FL), Rhodamine B (RD), 1,1′-dioctadecyl-3,3,3′,3′-
tetramethylindocarbocyanine perchlorate (DiI), polyethylene glycol monomethyl ether 
methacrylate (PEGMA) 500 g/mol, 2-aminoethyl methacrylate hydrochloride (AEMA), 4-cyano-
4-(phenylcarbonothioylthio)pentatonic acid, and 2,2’-azobis(2-methylpropionitrile) (AIBN) were 
purchased from Sigma Aldrich. 1,1'-dioctadecyl-3,3,3',3'-tetramethylindodicarbocyanine, 4-
chlorobenzenesulfonate salt (DiD), and 3,3'-dioctadecyloxacarbocyanine perchlorate (DiO) were 
purchased from ThermoFisher Scientific. Phospholipids and sterols; 1,2-dioleoyl-sn-glycero-3-
phosphocholine (DOPC), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine 
rhodamine B sulfonyl) ammonium salt (PE-RD), 1,2-dioleoyl-sn-glycero-3-
phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] ammonium salt (PE-PEG), and 
cholesterol (CHOL) were purchased from Avanti Polar Lipids Inc. mPEG-Thiol, MW 2,000 (PEG-
SH) was purchased from Laysan Bio Inc. AIBN (2,2’-azobis(2-methylpropionitrile) was purified by 
recrystallization, while all other listed reagents were used without further purification. Pyridyl 
disulfide ethyl methacrylate (PDSMA) was prepared as previously reported.126   
4.2.2 Instrumentation  
All size analysis was done using dynamic light scatting (DLS) on a Malvern Zetasizer 
Nano ZS.  Bulk sample UV-Vis absorption was monitored on a PerkinElmer Lambda 35 
spectrometer, bulk fluorescence was performed on a PerkinElmer LS 55 spectrometer. 1H-NMR 
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spectra were recorded on a 400 MHz Bruker NMR spectrometer using the residual proton 
resonance of the deuterated solvent as the internal standard. Polymer molecular weights were 
estimated by gel permeation chromatography (GPC, Waters) using THF as eluent at a flow rate 
of 1 mL/min by a refractive index detector compared to poly(methyl methacrylate) (PMMA) 
standard.  
4.2.3 Calcein-LS (CC-LS) formation  
LSs were composed of a 60:40:1:0.1 molar ratio of DOPC:CHOL:PE-PEG:PE-RD  [DOPC 
(1.2 mg, 1.5 μmol), CHOL (0.4 mg, 1.0 μmol), PE-PEG (70 μg, 25 nmol), (3.2 μg, 2.4 nmol)]. All 
LSs were made to have a final hydrated lipid concentration of 2.5 mM. Lipid and sterol 
components were mixed in chloroform and vortexed before being dried into a film with an argon 
stream. Films were further dried under vacuum overnight before being hydrated with 1 mL PBS 
containing CC (40 mM) at 2-8 °C for 3 hours; vortexing initially and every hour throughout the 
hydration period. Following hydration, LSs were extruded 21 times through a polycarbonate 
membrane (100 nm; 19 mm) using a mini-extruder set (Avanti Polar Lipids Inc.). CC loaded LSs 
(CC-LSs) were purified via dialysis (SnakeSkin MWCO 10 KDa, Thermo Fisher Scientific) in a 
saturated sodium bicarbonate solution at room temperature to remove free CC. Purified CC-LSs 
were stored at 2-8 °C until further use.  Concentration for CC-LSs analyses are reported with 
respect to lipid molarity unless otherwise noted. 
4.2.4 Amphiphilic random copolymer synthesis  
4.2.4.1 Synthesis of p(PEG-r-PDS)  
Random copolymer p(PEG-r-PDS) was synthesized following a previously reported 
method.73 To a schlenk-flask, PDSMA (400 g, 7.79 mmol), PEGMA (1.642 g, 3.28 mmol), 4-cyano-
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4-(phenylcarbonothioylthio)pentanoic acid (49 mg, 0.13 mmol), and AIBN (4 mg, 0.025 mmol) 
were dissolved in THF (7 mL). Reagents degassed by performing three freeze-pump-thaw cycles 
before stirring for 24 h at 70 °C.  The reaction was quenched by submerging in an ice bath, and 
polymer purified via dialysis (regenerated cellulose, MWCO 3500, Fisher Scientific) against 
dichloromethane for 48 h.  Polymer solution was dried under vacuum to yield the random 
copolymer, p(PEG-r-PDS) as an oil (Scheme 0.1). GPC (THF) Mn: 19.8 kDa. Ð: 1.6. 1H NMR (400 
MHz, CDCl3) δ: 8.42, 7.63, 7.07, 4.33-3.93, 3.73-3.44, 3.34, 2.99, 208 -1.50, 1.30-0.67 ppm. The 
molar ratio of the two monomers in the polymer were determined by relative integrations of the 
aromatic protons of PDS and methoxy protons of OEG to give 3:7 (PEG:PDS).  
 
Scheme 0.1 Synthesis of p(PEG-r-PDS) 
4.2.4.2 Synthesis of p(PEG-r-PDS-r-A) 
Synthesis of random copolymer p(PEG-r-PDS-r-A) was done following the p(PEG-r-PDS) 
synthetic procedure. To a Schlenk-flask, PDSMA (1.988 g, 7.79 mmol), PEGMA (1.642 
g, 3.28 mmol), AEMA (60 mg, 0.36 mmol), 4-cyano-4-(phenylcarbonothioylthio)pentanoic acid 
(49 mg, 0.13 mmol), and AIBN (4 mg, 0.025 mmol) were dissolved in DMF (7 mL). Reagents 
degassed by performing three freeze-pump-thaw cycles before stirring for 24 h at 70 °C.  The 
reaction was quenched by submerging in an ice bath, and polymer purified via dialysis 
(regenerated cellulose, MWCO 3500, Fisher Scientific) against dichloromethane for 48 h.  
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Polymer solution dried under vacuum to yield the random copolymer, p(PEG-r-PDS-r-A), as an 
oil. GPC (THF) Mn: 16.5 KDa; Ð: 1.4. 1H NMR (400 MHz, Acetone-D6) δ: 8.52, 7.84, 7.27, 4.46-4.04, 
3.82-3.43, 3.32, 3.20, 2.80, 2.01-1.76, 1.43-0.87. The molar ratio of the two monomers in the 
polymer were determined by relative integrations of the aromatic protons of PDS, methoxy 
protons of PEG, and methylene protons of AE to give 32:60:8 (PEG:PDS:A). (Scheme 0.2) 
 
Scheme 0.2 Synthesis of p(PEG-r-PDS-r-A) 
4.2.5 Simulated GI fluid model 
Simulated GI fluids were adapted from previously reported in vitro digestion models127–
129  to make simulated saliva, gastric, and intestinal fluids. Methods were modified to characterize 
nanomaterial solution stability via bulk DLS, fluorescence spectroscopy, and UV-Vis 
spectroscopy analysis. Conditions for the simulated mouth (saliva), stomach (gastric), and 
intestine are further described below.  
4.2.5.1 Simulated saliva fluid (SSF) 
Simulated saliva fluid (SSF) was composed of a saliva salt solution (SSS) composed of 
sodium chloride (399 mg), ammonium nitrate (82 mg), potassium dihydrogen phosphate (159 
mg), potassium chloride (51 mg), potassium citrate (5.3 mg), urea (50 mg), D-L-lactic acid sodium 
salt (37 mg), and porcine gastric mucin (type II) (7.5 g) dissolved in 250 mL phosphate buffer. 
Solution pH changed to 6.8 with concentrated sodium hydroxide before filtering (0.22µm GP, 
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Millipore Express PLUS, Fisher Scientific) to yield SSS, which was stored at 2-8 °C until further 
use. Porcine gastric mucin (Type II) (300 mg) was mixed with SSS (10 mL) for 12-16 h at room 
temperature to yield the SSF used in experimentation.  
4.2.5.2 Simulated gastric fluid (SGF) 
Simulated gastric fluid (SGF) was composed of a gastric salt solution (GSS) sodium 
chloride (200 mg), concentrated hydrochloric acid (0.7 mL), and pepsin A (320 mg) dissolved in 
Mili-Q water (100 mL). Solution pH decreased to 1.2 with concentrated hydrochloric acid and 
filtered (0.22 µm GP, Millipore Express PLUS, Fisher Scientific) to yield working GSS, which was 
stored at 2-8 °C until further use. SGF was made from pepsin (32 mg) and GSS (10 mL), which 
were mixed at room temperature 30-40 min before experimentation.   
4.2.5.3 Simulated intestinal fluid (SIF) 
Simulated intestinal fluid (SIF) contained a combination of intestine salt solution (ISS), 
bile salt solution (BS), and/or lipase solution (LS).  ISS was composed of calcium chloride (5.5 g), 
sodium chloride (32.9 g), and Mili-Q water (150 mL), which was mixed and stored at room 
temperature until further use.  BS contained bile extract (110 mg), phosphate buffer (10 mL, 50 
mM, pH 7), which was mixed and stirred at room temperature for 16-24 h before sample testing. 
LS contained lipase (28 mg) and phosphate buffer (10 mL, 50 mM, pH 7), which were mixed 30 
min before experimentation. Traditional SIF contains ISS, BS, and LS, (ISS+BS+LS) although due 
to precipitation we used solutions individually and in combination (e.g. ISS, BS, LS, ISS+BS, 
ISS+LS ISS+BS+LS) which are noted in individual experiments. 
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4.2.6 LS stability in SGF 
LS stability in SGF was determined from dispersing CC-LSs (0.1 mM) or CC (3 nM) within 
PBS or SGF. After 24 h, bulk solutions were monitored via DLS, UV-Vis spectroscopy, and 
fluorescence emission spectroscopy (excitation 460 nm) without any further dilution.  
4.2.7 Hydrophobic guest stability in GI fluids 
Hydrophobic guest stability in GI fluids was done using p(PEG-r-PDS) polymer 
aggregates (PAs) loaded with 1 % FL, RD, DiO, DiI, or DiD. Dye molecules (14-28 µL, 3.5-7 mg/mL 
in acetone) were added to a solution of polymer in PBS (10 mg) in PBS (1 mL). Solutions stirred 
at room temperature for 3 h, syringe filtered, and stored at 2-8 °C until experimental use. Dye 
loaded PAs were diluted with PBS, SSF (0.5 mL SSS, 0.48 mL PBS), SGF (0.5 mL GSS, 0.48 mL 
PBS), or SIF (0.05 mL BS+ISS, 0.93 mL PBS). UV-Vis spectroscopy analysis was done for each 
solution to determine decrease or shift in dye absorption. Similarly, fluorescence emission was 
also monitored for FL, RD, DiO, DiI, and DiD using excitations of 430, 470, 430, 500, and 610 nm 
respectively.   
4.2.8 Amphiphilic nanogel (ANG) formation and stability in GI fluids 
ANG stability in GI fluids was determined from monitoring FRET of p(PEG-r-PDS-r-A) 
ANGs containing DiI (DiI-ANG) or DiD (DiD-ANG). p(PEG-r-PDS-r-A) (10 mg) was dissolved in 
PBS (1 mL) and loaded with 5 % dye (9.4 µL, 10 mg/mL in acetone) to make PAs. PAs were 25 % 
crosslinked by adding DTT (3.34 mg, 2.3 µmole) and stirring for 1 h. 4 µL sample was diluted to 1 
mL with PBS and UV-Vis absorption was checked before and after excess DTT (10 uL, 500 
mg/mL) addition to confirmed samples were 25 % crosslinked.  In samples with additional 
PEGylation, PEG-SH (2.9 mg or 17.4 mg) was added and samples stirred an additional 24 h at 
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room temperature. 4 µL sample diluted to 1 mL with PBS and UV-Vis checked alone and with 
excess DTT (10 uL, 500 mg/mL) to determine % PEGylation (25 % or 50 %). All ANGs purified via 
dialysis (SnakeSkin MWCO 10 KDa, ThermoFisher Scientific). 
FRET analysis was done by first mixing DiI- and DiD-ANGs (1:1 ratio, 8 mg/mL ANG). 
Mixed ANGs were further diluted at a 1:1 ratio with desired testing solution to have a final ANG 
concentration of 4 mg/mL throughout testing. Testing solutions consisted of PBS, SSF, SGF and 
SIF (ISS+BS+LS). At desired time points aliquots from ANG-PBS/SSF/SGF/SIF mixtures were 
removed and diluted with PBS to a final ANG concentration of 72 µg/mL. Sample dilutions 
syringe filtered and tested directly via UV-Vis and fluorescence spectroscopy. Fluorescence 
emission was collected at an excitation of 480 nm.  
4.3 Results and discussion 
4.3.1 Stability of CC-LSs in PBS vs. SGF 
Initial monitoring of LS stability was done using DOPC:CHOL:PE-PEG LSs, which were 
loaded with hydrophilic guest, CC (Figure 0.3). Lipids were dried into films, hydrated, and 
extruded as with an aqueous solution containing CC. Subsequent removal of free CC was then 
done via dialysis to obtain pure CC loaded LSs (CC-LSs).   
Since CC will self-quench when trapped within LSs, we used this as means to characterize 
CC encapsulation and/or release from LSs. To confirm CC was fully encapsulated within CC-LSs 
we made a solution of CC within PBS that had similar absorption to the CC-LS. Despite the 
absorption being the same, the fluorescence in CC-LSs was very minimal in comparison to free 
CC. This phenomenon confirmed CC was self-quenched and fully entrapped within the CC-LSs 
(Figure 0.4).  
93 
 
Figure 0.3 CC-LS formation  
 
Figure 0.4 Confirming CC encapsulation within CC-LSs via (a) fluorescence and (b) UV-Vis 
The stability of CC was monitored through bulk fluorescence and UV-Vis absorption 
within PBS or SGF. Results observed that SGF greatly affected CC, as observed from the 
decreased fluorescence (Figure 0.5a) and absorption (Figure 0.5b) in comparison to CC within 
PBS. 
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Similarly, the stability of CC-LSs was also monitored within PBS and SGF via bulk 
fluorescence and UV-Vis absorption. Results observed that the fluorescence was mildly changed 
between PBS and SGF solutions (Figure 0.6a). Due to previously observing that SGF will decrease 
CC fluorescence, we were unsure if the minimal change in CC-LS fluorescence was due to actual 
protection of the CC in CC-LSs (as observed by self-quenching CC), or if the CC was simply being 
exposed to SGF (in return decreasing CC fluorescence). To confirm this, we turned to UV-Vis 
analysis, since if the CC was exposed to SGF, its absorption would also be effected. Interestingly, 
the UV-Vis absorption for CC-LS was unchanged whether in BPS or SGF. The lack of change in 
absorbance confirmed that the LS was indeed protecting the CC from SGF solution (Figure 0.6b). 
Additionally, DLS analysis was also done to confirm LS size was unaffected by the harsh SGF 
conditions (Figure 0.6c). 
 
Figure 0.5: Stability of CC in PBS (CC) vs. SGF (SGF-CC) via (a) fluorescence and (b) UV-Vis 
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Figure 0.6 Stability of CC-LS in PBS vs. SGF via (a) fluorescence, (b) UV-Vis, and (c) DLS 
Due to turbidity interference of the SSF and SIF with the LS solutions, we were unable to 
receive conclusive results showing the stability of LSs within simulated fluids using CC-LSs. To 
overcome this, we re-designed our analysis to take diluted aliquots of samples followed by 
filtrations before monitoring UV-Vis and fluorescence absorption, which was observed to 
decrease turbidity background from SSF and SIF components.  Additionally, the sensitivity of CC 
with simulated SGF fluids posed a challenge in monitoring guest and material stability with 
simulated GI fluids. For this reason, we explored the stability of various fluorescent dyes to 
determine the best model guests for monitoring ANG and guest stability in simulated GI fluids. 
Due to the higher stability of hydrophobic dyes we decided to do further GI guest and material 
stability analysis with our previously established amphiphilic random copolymer system.73,74,130 
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4.3.2 Stability of dyes in simulated GI fluids  
In order to characterize stability of hydrophobic guests within hydrophilic simulated GI 
solutions, we loaded them self-assembling p(PEG-r-PDS) polymer aggregates (PAs). PAs were 
loaded with 1 % of dye with respect to total polymer amount. Solubility and stability of dyes was 
characterized by monitoring bulk UV-Vis absorption and fluorescence for each dye in PBS along 
with dyes incorporated into PAs within PBS (P-PBS), SSF (P-SSF), SGF (P-SGF), or SIF (P-SIF). 
Monitoring the absorption of each dye within PBS versus being loaded within the PA within PBS 
(P-PBS) was evidence to, whether the dye solubility was enhanced by the PA.  Additionally, 
change in absorption or fluorescence signal provided means to determine if the guest molecule 
was effected by different simulated GI fluids. 
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Figure 0.7 GI stability via (fluorescence)/(UV-Vis) of (a)/(b)) RD and (c)/(d) FL  
Results revealed that FL and RD both displayed aqueous solubility, although FL solubility 
was mildly changed when incorporated within the PA (P-PBS), while RD solubility was greatly 
increased when incorporated within a PA (Figure 0.7a,c). FL absorption and fluorescence were 
greatly decreased when mixed with SGF and SIF, confirming this was not a sufficient model 
probe for simulated GI analysis (Figure 0.7). Despite the mixed solubility of RD within PBS and 
ANG, its absorption and fluorescence were only mildly changed after mixing with SIF (Figure 0.7), 
deeming this a much better probe than FL.  
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Figure 0.8 GI stability via (fluorescence)/(UV-Vis) of (a)/(b) DiO, (c)/(d) DiI, and (e)/(f) DiD  
Unlike FL and RD, DiO, DiI, and DiD were insoluble in PBS but well solubilized within PAs 
(P-PBS) (Figure 0.8a,c,e). Additionally, DiO, DiI, and DiD were stable within all solutions except 
the SIF, where both fluorescence and absorption were partially decreased (Figure 0.8b,d,f). 
Overall, we decided to use DiI and DiD as hydrophobic model guests to characterize stability of 
ANGs within simulated GI fluids. 
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4.3.3 Stability of ANGs with varied PEGylation in simulated GI fluids  
Stability of ANGs in simulated GI fluids was done using the p(PEG-r-PDS-r-A). The amine 
functionality served as a handle for future surface functionalization of ANGs. Changing the 
surface functionality provides means to enhance traceability, stability, and or permeability within 
simulated Caco-2 epithelial layers, although this phenomenon was not explored within this work. 
Initial analysis of ANG stability in GI fluids was done using self-assembling p(PEG-r-PDS-r-A), 
which were loaded with either DiI or DiD and subsequently crosslinked and/or further PEGylated. 
Due to the released PDS groups having an absorption at 340 nm, we used this as means to 
determine ANG % crosslinking and PEG-thiol functionalization, which coincided with a 
previously reported method.50 After excess DTT addition all PDS groups were cleaved providing 
an absorption representative to 100 % crosslinking. Comparing this absorption before and after 
excess DTT addition confirmed sample crosslinking density was 25 % in our ANGs.  In samples 
with additional PEGylation, PEG-SH was added to displace remaining PDS groups after 25 % 
crosslinking. Similar to determining % crosslinking, UV-Vis analysis of PDS (340 nm) before and 
after excess DTT addition was done to determine % of PEGylation to be 25 % or 50 %. (Figure 
0.9) 
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Figure 0.9 ANG formation and PEGylation 
FRET analysis was done on ANGs which were 25 % crosslinked containing either 0, 25, or 
50 % PEGylation. After mixing DiI- and DiD-ANGs the fluorescence and absorption was 
monitored to see change in FRET ratio and dye absorption over time. Analyses were done with 
ANG variations (0 % PEG, 25 % PEG, and 50 % PEG) in PBS, SSF, SGF, and SIF. Results showed 
that even within PBS, ANGs had guest exchange, although the absorption remained constant 
over time ensuring guests were not precipitating out of the ANG solution (Figure 0.10a-b). The 
FRET ratio over time was decreased with increasing PEGylation, which confirmed increasing 
PEGylation increases guest encapsulation stability of ANGs (Figure 0.10a).  
Similar trends in ANG stability were observed with SSF ( 
Figure 0.11) and SGF (Figure 0.12) in comparison to PBS. ANGs with 25 and 50 % 
PEGylation were slightly more affected by SGF than SSF, as observed by their higher FRET ratio 
over time (Figure 0.12a). Higher PEGylation increased ANG stability within SSF and SGF, 
although the stability of ANGs in PBS, SSF, and SGF were very similar overall.  
A much different trend in ANG stability was observed with SIF than other solutions (PBS, 
SSF, SGF). There was minimal difference in FRET ratio between the 1, 25, and 50 % PEGylated 
ANGs within SIF (Figure 0.13a). This was likely due from the guest molecule precipitating out of 
the ANG solution, as observed by the loss in DiD absorption over time (Figure 0.13b). Such results 
made it clear the ANG was greatly affected by SIF in comparison to SSF and SGF solution. Due 
to this, we decided to explore the ANG stability within the separate SIF precursor solutions, ISS, 
BS, and LS.  
101 
 
Figure 0.10 ANG stability in PBS via (a) FRET ratio and (b) DiD absorption over time 
 
Figure 0.11 ANG stability in SSF via (a) FRET ratio and (b) DiD absorption over time 
 
Figure 0.12 ANG stability in SGF via (a) FRET ratio and (b) DiD absorption over time 
0
0.2
0.4
0.6
0.8
0 5 10 15 20
F
R
E
T
	ra
ti
o
time	(h)
PBS
0	%	PEG
25	%	PEG
50	%	PEG
(a)
0
0.05
0.1
0.15
0 5 10 15 20
D
iD
	a
b
so
rb
a
n
ce
time	(h)
PBS
0	%	PEG
25	%	PEG
50	%	PEG
(b)
0
0.2
0.4
0.6
0.8
0 5 10 15 20
FR
ET
	ra
ti
o
time	(h)
SSF
0	%	PEG
25	%	PEG
50	%	PEG
0
0.05
0.1
0.15
0 5 10 15 20
D
iD
	a
b
so
rb
an
ce
time	(h)
SSF
0	%	PEG
25	%	PEG
50	%	PEG
(a) (b)
0
0.2
0.4
0.6
0.8
0 5 10 15 20
F
R
ET
	r
at
io
time	(h)
SGF
0	%	PEG
25	%	PEG
50	%	PEG
0
0.05
0.1
0.15
0 5 10 15 20
D
iD
	a
bs
or
b
an
ce
time	(h)
SGF
0	%	PEG
25	%	PEG
50	%	PEG
(a) (b)
102 
 
Figure 0.13 ANG stability in SIF via (a) FRET ratio and (b) DiD absorption over time 
To determine what was causing ANG stability within SIF, we monitored the absorption 
of DiI-ANGs over time within PBS, ISS, LS, BS, and SIF solutions. Results show that within 
individual solutions the absorption of DiI changes minimally over time when within PBS, ISS, LS, 
or BS (Figure 0.14). This was puzzling since the DiI absorption is almost exclusively eliminated 
when within a SIF solution, which is a combination of ISS, LS, and BS (Figure 0.14). When looking 
at the combination of ISS, LS, and BS, we do observe significant solution precipitation, prior to 
sample addition. With that, it is clear the combination of ISS, BS, and LS promotes coagulation 
and/or breakdown of materials within the intestinal fluids. Based on these finding, interactions 
of bile, lipase and/or salts seem to be a significant barrier to ANG stability within simulated GI 
fluids.  
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Figure 0.14 ANG stability in individual SIF solutions via (a) DiI absorption over time 
4.4 Conclusion and future outlook  
The conglomerate of proteins, carbohydrates, and salts within simulated GI fluids poses 
a challenge in characterizing nanomaterial stability in solution. In addition to testing stability of 
various dyes as model guests within simulated fluids, we showed initial stability analysis for a LS 
and ANG system. Both LS and ANG systems seem to be promising due to their high stability in 
PBS, SSF, and/or SGF. However, due to the surprising instability of ANGs within SIF, further 
characterization for both systems are necessary to determine the best LS and ANG formulation 
for stability within GI fluids. Future prospective for system design and characterization for these 
materials are described in more detail within Chapter 5.  
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CHAPTER 5 
 
SUMMARY AND FUTURE PERSPECTIVE 
5.1 Current and future outlook of polymer and lipid nanotherapeutics 
Understanding the biological barriers therapeutics need to overcome is vital to 
uncovering design features necessary for advancing clinical nanomedicines. The fast-growing 
knowledge on polymer nanotherapeutics, is quickly leading to chemical and physical guidelines, 
which have potential to re-shape the field of nanomedicine. Similarly, well established lipid-
based therapeutics can greatly expedite the clinical discovery timeframe for LSs and potentially 
LGs. Overall, utilizing pre-clinical and clinical reports are key in determining the specific 
guidelines necessary for future success of LS, LG, NG, and ANG as nanotherapeutic scaffolds. 
Regardless of material scaffold, successful nanotherapeutics rely on fundamental understanding 
of supramolecular structures, self-assembly characteristics, and the factors that dictate their 
interactions within the complex biological system. Throughout this work we highlighted the 
motivations for a LG system along with the process in which we followed to highlight their 
potential as a nanotherapeutic scaffold.  
5.2 Formulation and characterization of LG summary  
Within Chapter 2, we described the single-pot formulation of a dual-guest loaded lipogel 
(LG) scaffold. Various characterization techniques were used to determine initial formation, 
purification, guest encapsulation, and final stability.  We were able to utilize common dynamic 
light scattering and spectroscopy techniques along with multi-color fluorescence detection and 
imaging to quantify the effectiveness of guest encapsulation within our LG formulation in 
addition to material properties and stability. An important feature to our analysis, was that the 
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techniques had applicability with a variety of LG or complex nanoparticle systems. Specifically, 
fluorescently labeled lipids and model guest molecules were used within this LG system, which 
can be easily translated to better characterize various other lipid, polymer, and/or guest 
components within nanomaterials. Overall, the cocktail of characterization techniques used 
within this work hold immense potential in future characterization of complex nanomaterials in 
solution.  
5.2.1 Future perspectives of LG formulation and characterization 
Future prospective of this work are to expand in two main areas. The first area is 
expanding on the LG material scope. To truly deem this system as “tunable” it will be necessary 
to form a library of LG variations using our established methodology. An array of proteins and 
hydrophobic guest molecules beyond GFP/CA and DiI/DiD, respectively should be incorporated 
to broaden the encapsulation capabilities of LGs to varying sized and or functionalized guest 
molecules. Additionally, modifying the LG core/shell is also key to expanding the material scope. 
The polymer core characteristics should be systematically tuned for the current system (e.g. 
crosslinking density, concentration, monomer:crosslinker ratio). Determining the optimal 
polymer composition would lead into future modifications to broaden the NG scaffold scope to 
have varying chemical or physical properties (hydrophilicity, hydrophobicity, functionality, 
pH/temperature/light-sensitivity). Similarly, the LG lipid shell needs to be systematically tuned 
with varying lipid ratios and/or surface functionality to show the limits of which the LSs will 
template into LGs, while maintaining dual-guest encapsulation. Additionally, the lipid 
composition needs to be broadened to other lipid types to show the ability to control lipid shell 
density (e.g. gel-like vs. current liquid-like lipids), sensitivity (e.g. temperature, redox) and/or 
surface functionality (PEGylation, targeting ligand functionalized, charge). Beyond systematic 
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variations to show the scope of LGs, the next generation LGs should be composed of naturally 
occurring and fully degradable lipid and polymer materials, which would hold great impact in 
delivery applications. Overall tuning the core and shell properties could really highlight the future 
utility for this LG scaffold for both biological and material applications. Along these same lines, 
the second area of prospective work is to expand the capabilities of characterization techniques 
established within Chapter 2.  
Within the current LG system, the Cryo-EM morphology and TIRF analyses are two major 
areas worth expanding. In regard to LG morphology, inconsistencies have been observed when 
changing the UV-irradiation source used for NG core polymerization. Looking into the LS, NG, 
and LG morphology both individually and in combination throughout formation process steps 
would expand on the material properties and interactions that occur during LG formation. The 
best way to do this would be with Cryo-EM and/or Liquid Cell EM (LC-EM) to fully understand 
how each component interacts within solution during formation. In addition to solution phase 
LG components, it is necessary to see what happens to the material morphology, stability, and 
guest encapsulation after extensive liquid storage in addition to drying materials. Since typical 
commercially available nanomaterials are stored in dry form and/or have 3-6 months shelf-life, 
full characterization of LG stability before and after drying and/or re-dispersing into aqueous 
medium is necessary for better translation to an industrial setting. Beyond stability and 
morphology via EM, expansion of guest encapsulation and quantification via total internal 
reflection fluorescence (TIRF) microscopy is equally as beneficial.  
The ease of our TIRF analysis, which was also verifiable by bulk fluorescence and DLS, 
holds great potential as a simple and reliable technique for characterizing complex 
nanomaterials within solution. Since typical guest molecules will likely not be auto-fluorescent, 
it is crucial the characterization methods are expanded to lipids, polymer, and guest molecules 
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which are labeled with a fluorescent small molecule. With that, it is necessary to verity our 
established TIRF methods are translatable to quantifying individual and lipid/protein-conjugated 
small molecule dyes. Further guest molecule variations will also need to be accounted for in 
regard to sensitivity, which is described more below.  
5.3 Dual-stimuli responsive LG summary  
The stimuli-sensitivity, cytotoxicity, and intracellular uptake for the pH- and redox-
responsive LG scaffold was shown within Chapter 3.  We observed clear differences in sensitivity 
and cell uptake between pH-sensitive (DOPE:CHEMS) vs. non-pH-responsive (DOPC:CHOL) 
LGs. Additionally, redox-sensitivity of the NG core was confirmed by GSH cleavage of NGs. 
Throughout pH- and redox-sensitive analyses we also confirmed the lipid shell was indeed 
helping protect the NG core from cleaving. Toxicity analysis demonstrated that LGs were 
inherently non-toxic, and readily underwent endocytosis, which was preferential with pH- and 
redox-sensitive LGs. Despite these findings, monitoring the dual-sensitivity and dual-guest 
release of LGs was a major challenge to this work. Due to this, it is key to establish additional 
characterization techniques for characterizing stimuli-sensitivity and guest release from LGs, for 
applicability to different stimuli and/or routes of delivery.   
5.3.1 Future perspectives of stimuli-responsive LGs 
Similar to within Chapter 2 future perspectives, extending EM and TIRF characterization 
techniques could greatly expand on Chapter 3 results. Due to the complex nature of LGs, 
establishing methods to monitor their changes and guest release within solution would positively 
impact LG characterization in addition to having applicability towards characterizing other 
complex nanomaterials. Beyond typical LG components (polymer, protein, lipid), incorporation 
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of a heavy atom label or guest would be of great use in characterizing material sensitivity via Cro-
EM or LS-EM.  We have preliminary characterization, which confirms we are able to see 
morphology changes in LGs after exposure to pH or redox stimuli. Better understanding of this 
instability and materials properties in real-time can be achieved by extending LG 
characterization to LC-EM. This way we are able to monitor the LG before, during and after 
exposure to stimuli. Similar with Cro-EM, we have also obtained preliminary results to display 
stimuli-sensitivity can also be monitored via TIRF microscopy.  
We have found that LGs remain adhered to the glass plate within a TIRF flow chamber. 
This allows for monitoring the LG before, during, and after exposure to different stimuli 
containing solutions. Initial results revealed changes in LGs after different stimuli containing flow 
through, although results are inconclusive due to pH and/or redox sensitivity of fluorescent guest 
molecules within the current LG system. With that, it is necessary redesign the fluorescent guests 
and/or covalent tags to better withstand an array of biological stimuli. Doing this would allow for 
easily expanding TIRF characterization and quantification methods to monitor stability and guest 
release of stimuli-sensitive LGs. Overall establishing stable model guests and developing TIRF 
characterization of LG sensitivity, would be applicable towards an array of stimuli-sensitive 
nanomaterials, beyond simply pH- and/or redox-sensitive LGs.  
5.4 Lipid and polymer materials for oral delivery summary 
The cocktail of proteins, carbohydrates, and salts within gastrointestinal (GI) fluids pose 
a challenge in characterizing nanomaterial oral stability. This was reiterated within Chapter 4, 
which focused on establishing a simulated GI fluid model in addition to potential guest probes, 
which would be ideal for characterizing nanomaterial oral stability. Initial characterization of LS 
and ANG oral stability was done using the modified simulated GI model. Both LS and NG systems 
109 
appeared stable within simulated saliva (SSF) and gastric fluids (SGF), although significant 
instability was detected when in simulated intestinal fluids (SIF). The breakdown of SIF, revealed 
that this instability was due to the cocktail of SIF components together, which did not cause 
instability when alone. Overall, Chapter 4 highlighted the complexity of barriers materials need 
to withstand if orally administered, and initial findings provided a seedling of material designs to 
grow off of for both LGs and ANGs.  
5.4.1 Future perspective of LS, LG and NG scaffolds for oral delivery 
Consistency and accuracy of the established simulated GI fluid stability model needs to 
be confirmed with both LS and ANG systems. Beyond this, there are multiple avenues in which 
this work can be continued. Key areas are with specific material design (LS, LG, or ANG), in 
addition to expanding into monitoring nanomaterial GI permeability.  
Since material functionality and properties can greatly change its oral stability, LS, LG, 
and ANG materials should be systematically varied and re-characterized for GI stability. Within 
the LS system, further testing within all of the simulated GI fluids is necessary to determine future 
prospective LS designs. Based on results showing the increasing PEGylation increased stability 
of ANGs, a key characteristic to systematically tune is surface coating and functionality. With 
that addition of PEG or polysaccharide coating is highly likely to enhance LS GI stability. Beyond 
varying surface functionalization, systematic variation of the lipid composition is necessary to 
find the optimal lipid shell for oral stability. To do this stability should be monitored with 
systematic variation of sterol-to-lipid ratio in addition to varying lipid type to see is stability is 
enhanced with more rigid sterols or gel-like lipids with higher glass transition temperatures (Tg). 
Beyond the LS, it will be key to incorporate the polymer core within the LS to determine 
differences in oral stability/permeability between LSs vs LGs. In regard to ANGs and hydrophilic 
110 
NGs, the crosslink density and stimuli-sensitivity will be additional features to tune for finding 
optimal stability-to-sensitivity combinations applicable to both GI solution stability and 
mucus/epithelial permeability.  
Nanomaterial and biomolecule permeation through the GI epithelium remains a large 
challenge in oral nanotherapeutics. With that, it is crucial to determine absorption through GI 
epithelial cells in tandem to GI fluid stability. Since in vivo testing is not feasible at this 
optimization stage, a Caco-2 (human colon adenocarcinoma cells)131 permeability model will 
need to be established. Characterization of nanoparticle permeability is a key challenge to the 
permeability model. We anticipate that fluorescent tags and model probes, which withstand 
harsh simulated GI fluids, will be good candidates for permeability characterization.132 As with GI 
fluid stability, monitoring permeability has a breadth of variables, which should also be 
considered. Examples of this, is the additional complexity of tissue culture and growth medium, 
which is likely to interfere with fluorescence and/or nanomaterial analysis. With that, initial 
analysis of the stability and monitoring of LS, LG, and/or NGs within growth medium and 
monolayer cells will be crucial to establish methods for permeability characterization. Also, using  
Caco-2 permeability assays take extensive time (20-30 days per experiment), skill (tissue culture, 
co-culture, sensitive instrumentation) and effort (regular media changing, extensive cell growth 
for each analysis).  With that, benefit lies in using more stealthy LS and ANG systems, for  
establishing methods of Caco-2 monolayer toxicity/cell uptake, and subsequent Caco-2 epithelial 
permeability. Beyond variation of LS, LG, and ANG composition and functionality, effect of size 
on permeability should also be monitored. Since one of the greatest challenges to oral 
nanotherapeutics is their larger size, finding optimal size required for mucus/epithelial 
permeability will be key to a successful scaffold design.  
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5.5 Outlook 
Within this dissertation, we aimed to advance the field of lipogels by showing their 
capability of dual-guest encapsulation (protein and hydrophobic small molecule) with dual-
stimuli-sensitive character (pH- and redox-sensitive). The new techniques established to 
characterize LG formation, purity, and guest encapsulation within solution hold great potential 
utility in monitoring an array of nanomaterials in solution, beyond LGs. Our findings displayed 
the modularity of LGs, which provide means to control their stability, active targeting, and/or 
stimuli-sensitive guest release properties. Overall, the culmination of background and 
experimental results, verified LGs are a versatile scaffold with potential to deliver therapeutics 
via various routes of delivery, a feat that has yet to be reached with current nanotherapeutics.  
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APPENDICES 
APPENDIX A 
ADDITIONAL DATA FROM CHAPTER 2 
 
Figure 0.1: DLS of (a) crude LG (cLG) vs (b) pure LG (LG) 
 
Figure 0.2 Pure LG (a) fluorescence and (b) UV-Vis spectra for FRET analysis  
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Figure 0.3 Crude LG (a) fluorescence and (b) UV-Vis spectra for FRET analysis  
 
Figure 0.4 Pure LG + monomer/crosslinker (MC) (a) fluorescence and (b) UV-Vis spectra for 
FRET analysis  
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APPENDIX B  
ADDITIONAL DATA FROM CHAPTER 3 
 
Figure 0.5 pH 7.7 DOPE:CHEMS LG (a) fluorescence and (b) UV-Vis spectra for FRET analysis  
 
Figure 0.6 pH 6.8 DOPE:CHEMS LG (a) fluorescence and (b) UV-Vis spectra for FRET analysis  
 
Figure 0.7 pH 5.9 DOPE:CHEMS LG (a) fluorescence and (b) UV-Vis spectra for FRET analysis  
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Figure 0.8 pH 4.4 DOPE:CHEMS LG (a) fluorescence and (b) UV-Vis spectra for FRET analysis  
 
Figure 0.9 pH 7.7 DOPC:CHOL LG (a) fluorescence and (b) UV-Vis spectra for FRET analysis  
 
Figure 0.10 pH 6.8 DOPC:CHOL LG (a) fluorescence and (b) UV-Vis spectra for FRET analysis  
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Figure 0.11 pH 5.9 DOPC:CHOL LG (a) fluorescence and (b) UV-Vis spectra for FRET analysis  
 
Figure 0.12 pH 4.4 DOPC:CHOL LG (a) fluorescence and (b) UV-Vis spectra for FRET analysis  
 
Figure 0.13 LG (in PBS) (nLG) (a) fluorescence and (b) UV-Vis spectra for FRET analysis  
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Figure 0.14 Redox-LG (GSH-LG) (a) fluorescence and (b) UV-Vis spectra for FRET analysis  
 
Figure 0.15 Single image from top, middle, and bottom of HeLa cell for uptake of GFP-RD-LGs 
with GFP, RD, NB and/or PMDR overlaid 
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Figure 0.16: Single image from top, middle, and bottom of HeLa cell for uptake of GFP-RD-LGs 
with GFP, RD, DiD and/or LB overlaid  
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